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Major depressive disorder and cardiovascular disease are highly comorbid, and the 
presence of one disorder greatly increases the likelihood of the other.  Remarkably, depressed but 
otherwise healthy patients with no history of cardiovascular disease are as likely to have a heart 
attack as patients with established cardiovascular disease.  
Experimental studies have used chronic mild stress (CMS), a rodent model of depression 
that uses a series of unpredictable, intermittent, and variable mild stressors to induce anhedonia, 
one of the core diagnostic criteria for major depression.  CMS also induces a constellation of 
behavioral, physiological, and neuroendocrine responses that closely resemble those observed in 
depressed patients, including alterations in autonomic control of the heart marked by decreased 
heart rate variability (HRV).  Commonly prescribed antidepressants might not improve 
cardiovascular alterations associated with depression, even when depressive signs are 
ameliorated.  There is evidence, however, that candesartan, an angiotensin type 1 receptor 
(AT1R) antagonist (ARB) often prescribed for cardiovascular disorders, has anxiolytic and 
possibly antidepressant effects in animal models.   
To study the possible antidepressant effects of candesartan, we first established a robust 
rodent model of vulnerability to depression, since severity of depression is correlated with 
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severity of cardiovascular changes in humans.  We found that rats selectively-bred for low 
locomotor responses to a novel environment (bLR) were especially vulnerable to CMS-induced 
anhedonia and cardiovascular changes. Conversely, selectively-bred high-responder rats (bHR) 
were resilient to the behavioral and cardiovascular changes induced by CMS.   
Finally, we compared the effects of candesartan and the SSRI fluoxetine on CMS-
induced anhedonia and cardiovascular changes. We found that candesartan has profound 
antidepressant effects, including rapid reversal of anhedonia, and attenuated anxiety-like 
behavior. Furthermore, candesartan reversed cardiovascular changes, including clinically 
relevant markers of risk for cardiac mortality.  Thus the major findings of these studies are 
twofold:  (1) bHR/bLR rats exposed to CMS offer a robust model of the interactions of 
predisposition and environmental stress that may contribute to depression and comorbid 
cardiovascular disease and (2) candesartan and other ARBs may be novel therapies for the 
treatment of comorbid depression and cardiovascular disease, and may be more effective than 
traditionally-prescribed antidepressants such as SSRIs. 
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1.0  INTRODUCTION 
1.1 DEPRESSION AND CARDIOVASCULAR DISEASE ARE HIGHLY COMORBID  
Emotions, personality, and mood can have a tremendous impact on human physiology, and 
prolonged periods of emotional distress can have serious repercussions on long-term health.  A 
profound example of this interaction of psychology and physiology is the highly comorbid 
relationship between major depressive disorder and cardiovascular disease.  Incredibly, 
depressed but otherwise healthy patients with no history of cardiovascular disease are as likely to 
have a heart attack as patients with established cardiovascular disease [1, 2]. This relationship 
exists independent of common risk factors, such as increased body mass index, smoking, or 
preexisting cardiac pathophysiology [3]. Furthermore, depression is considered a significant risk 
factor for coronary heart disease and cardiac mortality [2-4].  In the six months following a 
myocardial infarction, mortality was 3.5 times higher in patients who were also depressed than 
those who were not [2].  The association between depression and cardiovascular disease is also 
bidirectional, and patients who have recently had a major cardiac event, such as a myocardial 
infarction are more likely to be diagnosed with depression.  Indeed, while approximately 2-9% of 
American adults suffer from depression, the prevalence of this disorder in patients recovering 
from myocardial infarction is between 20-40% [5-7].   Cardiovascular disease and major 
depression are currently two of the most detrimental disorders in developed countries and 
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prevalence of both disorders continues to rise [8, 9]. Although the comorbid, bidirectional 
relationship between depression and cardiovascular disease is gaining attention [10], many 
important questions regarding the relationship between the two disorders, and the mechanisms 
that might connect them, remain unanswered. 
1.2 MAJOR DEPRESSION: A DISORDER OF MOOD AND PHYSIOLOGY 
1.2.1 Diagnostic criteria for depression 
Major depressive disorder is a complex and devastating disorder with significant behavioral, 
physiological, and neuroendocrine alterations. It is estimated that somewhere between 20 - 25% 
of the population will suffer from some form of depression in their lifetime [11]. The Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) lists two main criteria of the disorder: 
persistent depressed mood, and anhedonia, a lack of or reduction in pleasure for things that used 
to be pleasurable.  A clinical diagnosis of major depression requires either both of these criteria 
or one of these criteria accompanied by a certain number of the following changes:  changes in 
body weight or appetite, changes in sleep pattern, low energy or fatigue, diminished 
concentration, feelings of worthlessness, guilt, or despair, or recurrent thoughts of death or 
suicide [12] (Figure 1).   
 3 
 
Figure 1: Diagnostic criteria for major depressive disorder, from the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV).  
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1.2.2 Physiological changes that co-occur with depression  
In addition to these diagnostic criteria, a number of neuroendocrine and physiological changes 
have been observed in depressed patients: increased levels of sympathetic activity, marked by 
increased norepinephrine excretion [13],  hyperactivation of the hypothalamic pituitary adrenal 
(HPA) axis [14-17], increased levels of immune factors, such as pro-inflammatory cytokines 
[18],  and cardiovascular changes, such as increased resting heart rate (HR) and decreased heart 
rate variability (HRV) [19-21] . Decreased HRV is an especially critical symptom of depression, 
as it is also used as a clinical marker for increased risk of cardiac mortality [22], and will be 
discussed in detail below.  
1.3 AUTONOMIC CONTROL OF THE HEART IS ALTERED IN DEPRESSION 
AND CARDIOVASCULAR DISEASE 
1.3.1 Normal autonomic control of the heart 
Heart rate is controlled by the sinoatrial (SA) node, a cluster of autorhythmic cells located in the 
right atrium of the heart, which generates electrical impulses that cause the heart to contract.  The 
SA node is often called the pacemaker of the heart, and receives neural input from both 
complementary branches of the autonomic nervous system (ANS).   The sympathetic branch of 
the ANS, also called the ―fight or flight‖ branch has excitatory effects on the periphery, working 
to mobilize the body to deal with the source of stress:  blood flow to muscles increases, digestion 
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is inhibited, and HR is increased.  The parasympathetic branch, sometimes called the ―rest and 
digest‖ branch, is generally inhibitory,  helping to return the body to rest after a stress, 
decreasing HR, and aiding in activities such as digestion, sexual arousal, and growth.   These 
dual branches of the ANS work together to modulate heart rate based on the state of the 
organism.  At rest, both branches are active, though the parasympathetic branch predominates to 
keeps HR at a rate that is lower than intrinsic SA node activity.  This is sometimes referred to as 
a parasympathetic ―brake‖ on HR, and allows an extra level of control over HR.  In times of 
stress, HR can be increased by inhibiting parasympathetic activity and increasing sympathetic 
activity; conversely, HR is decreased by increasing parasympathetic and inhibiting sympathetic 
activity.   The sympathetic and parasympathetic branches of the ANS are each controlled by 
brainstem areas of the central nervous system (Figure 2). Pre-sympathetic neurons in the 
brainstem (e.g. rostral ventrolateral medulla and raphe pallidus) project to the intermediolateral 
cell column in the spinal cord, which project in turn to the sympathetic ganglia that innervate the 
heart. The parasympathetic (i.e. vagal) branch originates in the nucleus ambiguus and dorsal 
motor nucleus. 
 
 6 
 
Figure 2: Schematic of sympathetic and parasympathetic control of the heart 
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1.3.2 Reduced heart rate variability is a marker of cardiac mortality risk 
In a healthy cardiovascular system, the sympathetic and parasympathetic branches of the ANS 
work to ensure proper cardiovascular function under the varying conditions experienced by the 
organism.  However, prolonged periods of chronic stress can have lasting effects on cardiac 
autonomic tone, characterized by an increase in sympathetic activity, a decrease in 
parasympathetic activity, or both.  Time-domain HRV is a measurement of the variability in time 
between heart beats [i.e., the standard deviation of the inter-beat interval (IBI)],  and reflects the 
interaction of sympathetic and parasympathetic influences on HR [22].  A reduction in HRV 
indicates a shift in sympathovagal balance toward higher sympathetic tone, and is a significant 
predictor of mortality following myocardial infarction [23, 24].   
Depression is highly comorbid with a number of cardiovascular disturbances that fall 
under the general term of cardiovascular disease.  Specifically, these include atherosclerosis, 
ventricular arrhythmia, myocardial infarction, and sudden cardiac death [7, 25-27]. Depression is 
also associated with increased risk of progression of heart failure [28].  Each of these 
cardiovascular pathologies, in turn, has been associated with prolonged sympathovagal 
imbalance, as measured by reduced HRV.  Reduced HRV is consistently reported after 
myocardial infarction, predicts future cardiac pathology such as ventricular arrhythmia and 
sudden death [29], and  is  associated with higher incidence of cardiovascular mortality [30, 31].  
 Indeed, reduced HRV predicts the progression of atherosclerosis even more reliably than 
common risk factors such as smoking status or lipid measurements [32].  Additionally, reduced 
HRV is frequently observed in medically well depressed patients and reductions in HRV are 
significantly worse in severely depressed patients [21, 33].  Indeed, major to severe depression 
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doubles the cardiac mortality risk, as predicted by reduced HRV, in patients who are otherwise 
medically healthy [1].   
While HRV in the time domain (discussed above) is useful as an index of overall 
autonomic influence of HR, frequency domain analysis of HRV can be used as an index of 
relative sympathetic and parasympathetic components that contribute to HRV.  Frequency 
domain analysis identifies and measures rhythmic fluctuations in HR, and examines power (e.g. 
variability) as a function of frequency.  The frequency distributions produced by this method are 
separated into frequency bands that have been shown to correspond to specific components of 
the ANS (Figure 3). Total power across the frequency spectrum is related to overall autonomic 
balance [22].  The high frequency (HF) band corresponds to the respiratory frequency, and is 
used as an index of vagal or parasympathetic influence on HRV [22, 34].  Low  frequency (LF) 
HRV is  influenced by sympathetic and parasympathetic elements [22, 35] and very low 
frequency (VLF) power likely reflects modulation by the renin-angiotensin system [29, 35, 36] 
or its effects on parasympathetic influence on the heart [36].  Reduced VLF is an especially 
useful measure, as it strongly predicts cardiac mortality, and accounts for up to 30% of the 
mortality risk of depression after myocardial infarction [31].  
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Figure 3: Diagram demonstrating the concept of frequency domain analysis.   
Frequency domain analysis first separates waveform data (Fig 3A) into its component frequencies (Fig 
3B) and then identifies and quantifies the amount of fluctuation (i.e. variability) in HR that is accounted 
for by a given frequency band.  Pharmacological studies have shown that these frequency bands can be 
used as an index of autonomic function (Fig 3C).  
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1.4 ANIMAL MODELS OF DEPRESSION: UNPREDICTABLE CHRONIC MILD 
STRESS 
The comorbid relationship between depression and cardiovascular disease has been identified 
and firmly established because of important work in clinical and epidemiological research [2-4, 
6, 10, 20, 37-45].  However, work in experimental animal models has significantly contributed to 
a more complete understanding of the mechanisms that are common to both disorders.  Of the 
available animal models of depression, one of the currently best-validated is the chronic mild 
stress (CMS) model of depression used in rodents [46, 47].  In this model, an animal is exposed 
to a variety of mild, yet unpredictable, stressors over the course of many weeks.  CMS induces a 
constellation of altered behavioral, physiological, and neuroendocrine responses that closely 
resembles aspects of human depression [46]. The unpredictable nature of CMS is critical, and 
predictable stress has been shown to have an opposite effect, improving measures of mood and 
cognitive function in rats [48]. Depression-like behaviors have been evaluated by measuring 
anhedonia, one of the core signs of depression [12].  Anhedonia has been operationally defined 
using a variety of measures, including decreases in sucrose preference [49-53], approach to 
palatable food [54], brain stimulation reward [47, 55], and even palatable food-induced 
dopamine release in nucleus accumbens and prefrontal cortex [56, 57].  CMS-induced anhedonia 
is reversed by chronic, but not acute, administration of common antidepressants [46, 47, 53, 58-
63], demonstrating that CMS is an appropriate model for studying the effects of chronic 
antidepressant treatment. CMS has proven to be a very useful tool for studying physiological and 
neural alterations that may take place during the development of depression [58, 64-66].  For 
instance, a series of studies that used CMS to induce anhedonic behavior in rats also reported 
changes in cardiovascular function that parallel those observed in depressed patients, including a 
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small increase in HR, decreased HRV, and an increased susceptibility to arrhythmia [49, 53, 67, 
68].  However, a common criticism of the CMS model is that results can vary across 
experiments, even within labs.  Indeed, in preliminary experiments performed in our lab, CMS-
exposed rats had a modest but significant decrease in sucrose preference, which was variable 
across individual rats.  Furthermore, preference for sucrose was positively correlated with pre-
CMS locomotor activity in an open field.  These results suggested that individual differences in 
behavioral traits might predispose certain rats to be vulnerable or resilient to the anhedonic 
effects of CMS.  
1.4.1 Modeling vulnerability to depression: High- and low-responder rats 
Although factors such as major life stress certainly contribute to the onset of depression, some 
individuals are more likely than others to become depressed. Indeed, depression is most likely 
aused by a complex interaction of genetic predisposition and environmental factors, and 
epidemiological studies estimate that genetic factors account for approximately 40-50% of risk 
for depression [11, 69]. Most individuals experience stressful life events, yet only a portion of 
individuals will experience serious anxiety or depressive disorders as a result of these events 
[70].   
1.4.2 Novelty-seeking predicts emotionality in screened supplier-bred rats 
One way to approach the issue of vulnerability and resilience has been to correlate baseline 
individual differences in behavior with either vulnerability or resistance to markers of mood 
disorders (e.g. behavior, genes) [71-75].   For instance, based on locomotor activity in a novel 
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environment, Sprague-Dawley rats can be classified as either high-responders (HiR), which have 
high levels of exploration, or low-responders (LoR) which have low levels of exploration [71, 
74, 76-78].  Since low exploratory activity is interpreted as a sign of anxiety-like behavior due to 
rodents’ innate aversion to novel, open spaces, it is not surprising that this classification predicts 
emotional reactivity in other behavioral tests.  Rats classified as LoR have higher anxiety-like 
behavior than HiR rats in tests such as the elevated plus maze (EPMZ) and the light-dark box 
[71, 76, 79, 80]. 
1.4.3 Selectively-bred rats represent the extreme ends of a spectrum of behavior and 
mood  
One approach that has been used to study trait differences in rats is to selectively breed animals 
at the opposite end of the normal distribution, and this strategy has recently been applied to 
locomotor activity in a novel environment.  These selectively-bred strains (bred HiR [bHR] and 
bred LoR [bLR], respectively) are thought to represent the extremes of the normal distribution of 
the Sprague-Dawley population.  Individual differences in anxiety-like behavior persisted and 
intensified as rats were selectively-bred on the trait of LoR or HiR [71, 81], making them a 
convincing model of inherited susceptibility or resilience to mood disorders.  Indeed, as the 
results in Chapter 2 demonstrate, bHR and bLR rats appear to be resilient and susceptible, 
respectively, to CMS-induced depression-like symptoms, and CMS-exposed bLR are an 
especially robust model of anhedonic behavior.  
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1.5 ANTIDEPRESSANT TREATMENT: HOW CAN YOU MEND A BROKEN 
HEART? 
If depression and cardiovascular disease are connected, does treating depression also improve 
decreased HRV?  In the case of tricyclic antidepressants, the answer is decidedly no, as those 
drugs are known to have cardiotoxic properties [82-84], leading doctors to discourage their use 
in patients that are especially vulnerable to cardiovascular dysfunction [85, 86].  In the case of 
selective serotonin reuptake inhibitors (SSRIs), reports are much less clear.  Some studies have 
reported that SSRIs improve cardiovascular outcomes and reduce mortality [19, 87], while others 
have found that SSRIs do not improve mortality risk, even when depression is in remission [88]. 
Finally, some studies have reported that SSRIs may actually exacerbate cardiac mortality, 
especially when administered in conjunction with beta-blockers, which are commonly prescribed 
for various cardiovascular disorders [89]. Cognitive behavioral therapy also improves signs of 
depression but does not alter cardiac mortality [90].  These varied results present the troubling 
possibility that in some individuals the cardiac mortality risk associated with depression may 
persist even when depression is treated.   
1.6 THE RENIN-ANGIOTENSIN SYSTEM IN STRESS AND DEPRESSION 
Many hormonal and neurohumoral systems are activated in both depression and heart disease.  
One of these systems is the renin angiotensin system (RAS), which has an established role in 
cardiovascular regulation [91, 92]. Heightened levels of angiotensin II, the peptide that mediates 
the effects of the RAS, are considered a risk factor for heart failure [93], and can directly damage 
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cardiac myocytes [94].  Furthermore, drugs that inhibit the RAS such as angiotensin II type 1 
receptor (AT1R) blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors have 
been shown to reduce mortality from heart failure [95], possibly by reversing the reduction in 
VLF mentioned above [29, 35, 36].  
In rats, the RAS is also known to modulate both the HPA axis and the sympathetic 
nervous system responses to stress.  Angiotensin II increases sympathetic nerve activity, 
stimulates norepinephrine release, and directly activates sympathetic ganglionic cells [91, 96, 
97].  AT1Rs are located at every level of the HPA axis [98, 99], and blockade with a centrally-
acting ARB attenuates the HPA response to acute stress [100].  Chronic pretreatment with the 
ARB candesartan also greatly reduces anxiety-like behavior in rats [101], and prevents gastric 
ulceration associated with a chronic stress [102, 103].  
There is also some evidence that drugs that inhibit the RAS may have antidepressant 
properties.  There is some evidence indicating that ACE inhibitors improve mood and cognitive 
function in hypertensive patients [104, 105], and antidepressant use is lower in hypertensive 
patients taking ARBs or ACE inhibitors [106].  Finally, drugs that inhibit the RAS have positive 
antidepressant-like effects in the forced swim test in mice [107, 108], a behavioral test with high 
predictive validity for antidepressant drug efficacy.  
1.7 COULD AN ANTAGONIST OF THE RENIN-ANGIOTENSIN SYSTEM BE 
USED TO TREAT COMORBID DEPRESSION AND CARDIOVASCULAR DISEASE?  
Major depression and cardiovascular disease are highly comorbid, and depression is considered a 
significant risk factor for cardiac mortality.  In fact, severity of depression is correlated with a 
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reduction in HRV, a clinical marker of risk for cardiac mortality [33].  Thus individuals who are 
more vulnerable to depression may be also be at risk for increased vulnerability to cardiovascular 
dysfunction. We hypothesized that bHR/bLR rats would (1) provide a model of increased 
resilience or susceptibility to depression-like behavior brought on by the CMS model of 
depression (Chapter 2) and (2) susceptibility to depression-like behavior would be associated 
with significant changes in cardiovascular function, such as decreased HRV, particularly in the 
VLF range (Chapter 3).  Furthermore, typically prescribed antidepressants might not improve 
cardiovascular risk, though they reverse depressive behavior. We tested whether an antagonist of 
the RAS, a system known to be involved in both cardiovascular dysfunction and mood, would 
reverse both anhedonic behavior and changes in cardiovascular function induced by the CMS 
model of depression (Chapter 4). These studies demonstrate that bLR rats exposed to CMS 
provide a robust model for studying the relationship between depression and cardiovascular 
disease and present evidence that antagonists of the RAS alleviate both anhedonic behavior and 
cardiovascular changes induced by CMS.  
 
 
 16 
2.0  NOVELTY-SEEKING BEHAVIOR PREDICTS VULNERABILITY IN A 
RODENT MODEL OF DEPRESSION 
This chapter was published as:  Stedenfeld, K. A., Clinton, S. M., Kerman, I. A., Akil, H., Watson, 
S. J., Sved, A. F. Novelty-seeking behavior predicts vulnerability in a rodent model of 
depression. Physiol Behav. 2011,103:210-6.  
 
2.1 ABSTRACT 
The onset of major depressive disorder is likely precipitated by a combination of heredity and 
life stress. The present study tested the hypothesis that rats selectivity bred on a trait related to 
emotional reactivity would show differential susceptibility or resilience to the development of 
depression-like signs in response to chronic mild variable intermittent stress (CMS).  Male 
Sprague-Dawley rats that were bred based on the trait of either high or low locomotor activity in 
response to a novel environment were exposed to four weeks of CMS or control conditions. 
Changes in hedonic behavior were assessed using weekly sucrose preference tests and anxiety-
like behavior was evaluated using the novelty-suppressed feeding test. During four weeks of 
CMS, bred low responder (bLR) rats became anhedonic at a faster rate and to a larger degree 
than bred high responder (bHR) rats, based on weekly sucrose preference tests.  Measures of 
anxiety-like behavior in the novelty-suppressed feeding test were also significantly increased in 
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the CMS-exposed bLR rats, though no differences were observed between CMS-exposed bHR 
rats and their unstressed controls. These findings present further evidence that increased 
emotional reactivity is an important factor in stress susceptibility and the etiology of mood 
disorders, and that bHR and bLR rats provide a model of resistance or vulnerability to stress-
induced depression. Furthermore, exposing bHR and bLR rats to CMS provides an excellent way 
to study the interaction of genetic and environmental factors in the development of depression-
like behavior. 
2.2 INTRODUCTION 
Reliable animal models of depression are crucial to the success of preclinical studies of mood 
disorders such as major depressive disorder.  Chronic mild stress (CMS), an animal model of 
depression first developed in the late 1980’s, has gained favor in recent years for several reasons. 
First, it uses variable and unpredictable chronic intermittent stress, an established risk factor for 
depression [11, 109]. Second, it provokes changes in behavior and physiology that closely 
resemble the human disorder [46, 47]. Finally, CMS-induced depression-like signs can be 
reversed with antidepressant treatment [46, 60-62]. Additionally, the extended timecourse of the 
CMS paradigm, which typically lasts 4-6 weeks, is more appropriate for studying the effects of 
chronic drug treatment than acute measurements of so-called ―despair behavior‖ such as the 
forced swim test  [47, 110-113]. The depression-like behavior produced by CMS has typically 
been evaluated by measuring anhedonia, a key component of DSM-IV criteria for major 
depressive disorder. Reduced sucrose preference, for instance, can be reversed by chronic but not 
acute administration of anti-depressant drugs and is not changed by drugs that are ineffective as 
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antidepressants [58, 64, 65, 114]. The CMS model of depression in rodents strongly mimics both 
the symptoms of major depressive disorder and the time course of typical responsiveness to 
pharmacological treatment.  
However, environmental factors are not solely responsible for the onset of depression, 
and a key question in the study of mood disorders is that of vulnerability and resilience among 
individuals [70].  Researchers have begun to address this issue by examining baseline individual 
differences in behavior that correlate with either vulnerability or resistance to behavioral, 
genetic, hormonal, and molecular markers of mood disorders [71-75].  One behavioral trait that 
has been examined in this regard in rats is locomotor behavior in novel environments [71, 74, 76-
78].  Outbred Sprague-Dawley rats can be classified based on their activity level in a novel 
environment. Rats classified as high-responders (HiR) have high levels of exploratory activity, 
whereas rats with low activity in a novel environment are classified as low responders (LoR).  
Low exploratory activity is interpreted as a sign of anxiety-like behavior due to rodents’ innate 
aversion to novel, open spaces. Likewise, increased exploration is considered indicative of less 
anxiety-like behavior. Since the HiR/LoR designation is based on exploration of a novel 
environment, it is not surprising that this classification predicts emotional reactivity in other 
behavioral tests. Specifically, outbred rats classified as LoR have higher anxiety-like behavior 
than HiR rats in the elevated plus maze, light-dark box, and the open field test [71, 76, 79]. LoR 
rats’ tendency toward higher emotional reactivity is also apparent in the forced swim test, in 
which they display more depression-like behavior than HiR rats [80].   
In order to study the possible interaction of genetics and behavioral phenotype in HiR 
versus LoR animals, rats have been selectively bred based on that trait [71, 81].  These 
selectively-bred strains of each type (bred HiR [bHR] and bred LoR [bLR], respectively) 
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represent the extremes of the normal distribution of the Sprague-Dawley population. The 
patterns of anxiety- and depression-like behavior discussed above have been preserved and 
enriched across generations of bHR and bLR rats [71, 81], raising the possibility that the 
bHR/bLR rat strains may represent a model of inherited susceptibility or resilience to mood 
disorders.  We therefore hypothesized that studying bHR/bLR rats in the CMS model of 
depression would reveal an interaction of genetic predisposition and environmental stress, 
providing a model of vulnerability or resilience to stress-induced depression. 
2.3 EXPERIMENTAL PROCEDURES 
Animals and Housing 
Rats (male, Sprague-Dawley) used in this study were selectively-bred for locomotor traits 
according to procedures outlined in Stead et al., 2006 [71] and Clinton et al., 2007 [81]. These 
rats were from the F20 generation bred at the Molecular and Behavioral Neuroscience Institute at 
the University of Michigan; 16 Low-Responder (bLR) rats and 15 High Responder (bHR) rats 
were shipped to the University of Pittsburgh when they were approximately 3 months old (400-
450g). Prior to shipping, locomotor activity in a novel environment similar to the housing cage, 
was tested in all rats.  All subsequent testing was performed at the University of Pittsburgh. Rats 
were housed individually in plastic cages (length x width x height: 40 x 22 x 19 cm) with 3-5 cm 
of bedding (course cut Aspen chips; P.J. Murphy) and wire lids. Standard rat chow (Purina) and 
tap water were available ad libitum. Rooms were kept at a constant temperature of 23C under 
12 h light: 12 h dark lighting conditions (lights on at 0700). CMS-exposed and Control groups 
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(see descriptions below) were housed in separate rooms under similar conditions. The University 
of Pittsburgh Animal Care and Use Committee approved all animal protocols that were used. 
 
Chronic Mild Stress Protocol 
After a two-week period to collect baseline measurements, rats were either exposed to CMS for a 
total of 5 weeks, or were handled according to standard animal care practices (Control group). 
CMS and Control groups were single-housed in separate rooms.  The following individual 
stressors were used in the CMS protocol in varying order across different weeks (Figure 4): 
continuous overnight lighting; overnight water deprivation (18h) followed by 1 hour of empty 
water bottle replacement; 40-degree cage tilt; stroboscopic lighting (2-6 h; Chauvet mini-strobe 
CH-730; 8-12 flashes per second, 35 watts); overnight paired housing with another CMS-
exposed rat (18h); damp bedding (300-500mL lukewarm water added to cage bedding); white 
noise (radio static, 85dB, 1-4 h, continuous or intermittent); and predator odor exposure (30-60 
minutes exposure to 20uL undiluted 2,4,5-trimethylthiazoline (TMT; Pherotech Intl.) placed on a 
piece of filter paper and hung in each rat’s cage).  These mild environmental stressors were 
chosen to minimize the amount of interaction between experimenter and animal and have been 
shown in previous studies to be effective in inducing depression-like behaviors in rats [49-53, 58, 
68, 111].  All CMS rats were exposed to the same schedule of stressors, although the schedule of 
these stressors was altered on a weekly basis and multiple stressors occasionally overlapped.  
However, overnight food- and water-deprivation was only combined prior to the sucrose 
preference test (below).   
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Figure 4: An example of a typical chronic mild stress (CMS) schedule. 
 
CMS-exposed rats were exposed to a variety of intermittent stressors, which were applied each week, on 
different days and in different combinations. Control rats were housed in a separate room and were 
handled according to usual animal care protocols with the addition of a weekly sucrose preference test 
(SPT).  SPT was always administered on Friday.   
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Sucrose Preference Test 
The CMS protocol has been shown to decrease rodents’ preference for sweet solutions (see [46] 
for a review), which is thought to represent anhedonia, a core symptom of major depression [12]. 
This anhedonic behavior is commonly assessed in rats via the sucrose preference test (SPT) [49-
53, 64, 68, 114] and can be reversed by chronic antidepressant treatment [60-62].  To accustom 
the rats to the taste of sucrose, ad libitum water was replaced with 1% sucrose solution for one 
week. Tap water was returned one day before the first baseline SPT was administered. SPT was 
administered once per week to both CMS and Control groups.  Rats were food- and water-
deprived for 18 hours prior to the test.  Two graduated burets were placed on the cage filled with 
either 1% sucrose solution or tap water.  Rats were allowed to drink freely for one hour and total 
volume consumed was recorded.  Preference for sucrose was calculated as [(mL sucrose / total 
mL consumed) *100].  
 
Novelty-suppressed Feeding 
The novelty-suppressed feeding test (NSF) is often used as a measure of depression-like 
behaviors. Like the open field test, the NSF test is based on rodents’ innate fear of novel spaces.  
However, the NSF test introduces an additional component of motivation, as the food-deprived 
animal’s drive to eat conflicts with its fear of novel open spaces. Chronic, but not acute, 
administration of antidepressants reduces these latencies, giving the NSF test excellent predictive 
validity for the timecourse of antidepressant efficacy [64, 115, 116]. 
During CMS week 5, rats were food-deprived 24 hours prior to the test, with free access 
to water and were moved to the dimly lit testing room one to two hours before the test. Rats were 
placed into one corner of an open field apparatus (17 in. x 17 in. x 12 in.) with clear acrylic walls 
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and an opaque white acrylic floor.  Light level in the open field was maintained at 16-20 Lux and 
the walls and floor were wiped with Novalsan (chlorhexidine diacetate) between trials.  A food 
pellet was placed in the center of the open field and rats were placed in one corner. Latencies to 
approach and to begin eating were recorded with a limit of 15 minutes.  As soon as the rat was 
observed to eat, or the 15-minute time limit was reached, the rat was removed from the open 
field and placed in the home cage and observed until it began to eat in the home cage. Previous 
studies have demonstrated that home cage consumption is the same across treatment and control 
groups [64, 115, 116].  
 
Data Analysis 
Statistics were performed using Microsoft Excel and SPSS 16.0.  Values are expressed as mean 
± SEM.  For comparisons of four groups, 2-way ANOVA (strain*treatment) was used, with 
Tukey HSD post-hoc tests where appropriate. Repeated measures ANOVA was used to identify 
significant differences in SPT measures across time, also with Tukey HSD post-hoc test.  To 
compare proportion of animals in each group with SPT scores less than 50%, a 2-analysis was 
performed.  Pearson correlation was used to examine the relationship between body weight and 
sucrose preference or fluid intake. For all tests, a two-tailed p-value of 0.05 or less was 
considered significant.  
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2.4 RESULTS 
Body Weight 
Body weights were measured once per week, at the same time that food and water were removed 
prior to the weekly sucrose preference test.   At baseline, before exposure to CMS, there were no 
significant differences within strains (Table 1).  However, body weights were significantly 
higher in bHR rats than bLR rats (p<0.01), a difference that persisted throughout the experiment 
and that we have observed in previous populations of bHR/bLR rats (unpublished observation, 
Clinton, Kerman, Akil & Watson). There was also a significant difference between treatment 
groups (p<0.01) in the total amount of weight gained during the experiment.  While both strains 
of control rats gained similar amounts of weight, CMS-exposed rats did not gain weight during 
the experiment (Table 1).  
 
 
 
Table 1: Comparison of body weight at baseline and at each of four weeks of CMS 
 
*: p<0.01 compared to opposite strain 
**: p<0.01 compared to opposite treatment 
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Characterization of bHR/bLR rats 
To confirm behavioral phenotype, bHR (n=15) and bLR (n=16) rats that were used in this study 
were exposed to a novel environment before being shipped to the University of Pittsburgh.  As 
anticipated, bHR rats were markedly more active in a novel environment (Figure 5).  The two 
groups were further assigned to CMS-exposed or control groups (n=8 per group, except bHR-
Control n=7) and there were no baseline difference (p > 0.05) in locomotor scores between pre-
assigned treatment groups (Figure 5). CMS-exposed rats were exposed to a variety of intermittent 
stressors, which were applied each week, on different days and in different combinations. Control rats 
were housed in a separate room and were handled according to usual animal care protocols with the 
addition of a weekly sucrose preference test (SPT).  SPT was always administered on Friday.   
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Figure 5: bHR and bLR pre-CMS locomotor activity in response to a novel environment    
Prior to other experimental procedures, locomotor activity in response to a novel environment 
was tested.  There was a significant difference between bHR (n=15) and bLR rats (n=16) in 
baseline locomotor activity (p<0.01) but no difference within strains in the subgroups of rats that 
were subsequently exposed to CMS or not.  
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Exposure to chronic mild stress 
Rats of each rat strain were exposed to 4 weeks of intermittent CMS (Figure 4) and sucrose 
preference, used as a measure of anhedonia, was tested at weekly intervals.  At baseline, all 
groups had similar robust preference for 1% sucrose versus water. In control rats of both strains, 
sucrose preference remained stable during the experimental period.  In contrast, after two weeks 
of CMS, bLR-CMS rats showed significantly reduced sucrose preference (p=0.01; Figure 6) 
compared to both control groups and bHR-CMS rats (p=0.02), as well as their own baseline 
(p<0.001).   bLR-CMS rats had SPT scores that were significantly less than 50% (p<0.05), which 
persisted throughout the CMS period.  bHR-CMS rats did not have significantly reduced SPT 
scores until Week 4. Body weight was not correlated with either sucrose preference (r =.023, 
n.s.) or sucrose intake during the SPT (r = 0.37, n.s.).   
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Figure 6: Percent preference for sucrose across four weeks of CMS 
Sucrose preference was assessed at weekly intervals.  At baseline and Week 1, groups had no significant 
difference in sucrose preference.  bLR-CMS rats (n=8) had reduced sucrose preference compared to the 
other three groups starting in Week 2.  In Weeks 3 and 4 there was a significant Treatment x Strain 
interaction (p=0.02).  Values are means  SEM.  *:p<0.05 compared to other groups. 
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Performance in novelty-suppressed feeding test 
The NSF test was used as an additional measurement of depressive behavior [64, 115-117]. 
Latency to approach the food and latency to consume the food were recorded, with longer 
latencies in each parameter considered indicative of anxiety-like behavior [64, 115-117]. There 
was a significant interaction of strain and treatment; the bLR-CMS group scored higher on both 
measures, taking significantly longer to approach (Figure 7A) and begin to eat the food pellet 
(Figure 7B). In fact, only one of the eight bLR-CMS rats ate the food pellet within the 15-
minute time limit of the test. Scores were not significantly different between bHR-CMS rats and 
either control group (Figure 7A & 7B). All rats were observed eating chow within two minutes 
of being returned to the home cage, with no significant differences among groups. Finally, only 
bLR rats (both CMS-exposed and control) defecated during the NSF test, a factor that is often 
interpreted to indicate increased anxiety during behavioral tests [118-121].  
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Figure 7: Latency to approach and consume a food pellet in the novelty-suppressed feeding test 
Depression-related anxiety was further assessed in the Novelty-Suppressed Feeding test.  Following 24 h 
food deprivation, bLR-CMS rats had increased latency to approach (4A) and eat (4B) a food pellet placed 
in the center of an open field.  Values are means  SEM. *: Significant difference from opposite 
treatment. Significant difference from opposite strain.  7A: Latency to approach food pellet.  
Significant effects of treatment (p = 0.03) and strain (p = 0.05) as well as an interaction of the two (p = 
0.03) were found.  7B: Latency to eat food pellet.  Treatment, Strain, and Treatment*Strain: p<0.001 
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2.5 DISCUSSION 
The key observation from these studies is that rats selectively bred for low and high locomotor 
responses to a novel environment show markedly different susceptibility to develop signs of 
depression in response to chronic mild intermittent stress.  bLR rats showed signs of anhedonia 
sooner and to a greater degree than bHR rats, and this was confirmed with behavior in the NSF 
test, a test which is sensitive to antidepressant drugs [64, 117].  
 Supplier-bred Sprague-Dawley rats exhibit a range of behavior in novel 
environments [74, 122]. Based solely on this locomotor behavior, Sprague-Dawley rats can be 
separated into two groups: high-responders and low-responders (HiR & LoR), and these 
designations appear to predict emotional reactivity [71, 81]. The rats used in this study were 
selectively bred for novelty-seeking behavior in a novel environment over multiple generations. 
Differences in behavior and neurobiology have been well-characterized in bHR and bLR rats; in 
stressful or novel environments bHR rats have exaggerated locomotor activity, higher HPA 
activity and less anxiety [71, 81]. Additionally, bHR rats have increased drive for reward, are 
more inclined to self-administer drugs of abuse, and have higher dopaminergic tone in nucleus 
accumbens, compared to bLR rats [123, 124]. Based on these studies it has been postulated that 
differences in emotional reactivity between bHR and bLR rats represent a model of vulnerability 
to stress and mood disorders and may be a valuable tool for exploring genetic and environmental 
interactions of such disorders.  
 The current study used intermittent CMS as a model of stress-induced depression. 
CMS reproduces many of the complex symptoms typically observed in depressed human 
patients, including the core symptom of anhedonia, making it a highly useful animal model of 
depression [11, 46, 47, 60-62, 109-111, 113]. In rodents, anhedonia is most commonly measured 
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by a reduction in sucrose preference, which can be reversed by antidepressant drugs with a time 
course consistent with antidepressant efficacy and is not changed by drugs that are ineffective as 
antidepressants [58, 64, 65]. These results demonstrate the validity of the CMS time course in 
predicting antidepressant drug actions. After four weeks of CMS exposure, bLR rats showed 
significantly greater anhedonia, as compared to either bHR rats exposed to CMS or control (non-
CMS-exposed) groups of both strains.  It is notable that this reduction in sucrose preference in 
bLR rats occurred at a faster rate and to a greater degree compared not only to the bHR rats in 
this study, but also to supplier-bred Sprague-Dawley rats in studies from other labs [49-53, 68] 
including ours (Stedenfeld & Sved, unpublished observation). Furthermore, these scores were 
significantly less than 50%, the expected score if rats exhibited no preference for either sucrose 
or water.  It is possible, then, that this markedly reduced preference may reflect not only a lack of 
interest, but an actual aversion to the previously-rewarding sucrose solution.  Such extreme 
anhedonia is noted in severe cases of major depression in human patients, including the 
melancholic subtype [12, 125, 126], which may be more likely to occur following stressful life 
events and in patients with low sensation-seeking personalities [127-132].  The melancholic 
subtype also may be related to a reduction in reward processing [133, 134], paralleling similar 
observations in bLR rats such as a reduction in dopaminergic tone in nucleus accumbens [124] 
and decreased propensity to self-administer drugs of abuse [123].  Melancholic patients also 
display increased anxiety, increased HPA axis responses to stress [135, 136] and increased levels 
of stress-related neuropeptides in the paraventricular nucleus of the hypothalamus (PVN) [137]. 
Differences between bHR and bLR behavior were also seen in the NSF test, which is 
used to measure anxiety-like behavior as well as antidepressant efficacy [115, 116].  Although 
these may seem like two very different endpoints for a single test, there is, in fact a high rate of 
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comorbidity between anxiety disorders and depression [138, 139], and the two disorders share 
some overlapping characteristics such as irritability, sleep disturbances, and difficulty 
concentrating [12].   However, in addition to being a central symptom of anxiety disorders, 
anxiety itself is often a component of the negative affect associated with depression [140, 141].  
Although anxiety is not explicitly stated in the diagnostic criteria for major depression [12], up to 
90% of depressed patients report anxiety as a symptom [142].  Indeed, anxiety without 
depression is much more common than depression without anxiety [140, 141].   Depressed 
patients with anxiety symptoms at the time of remission are more likely to experience a relapse 
than patients without anxiety [143].  This is especially true in the melancholic subtype of 
depression discussed above [129, 130]. 
We found that bLR-CMS rats took a substantially longer time than bHR-CMS rats to 
approach and then to consume the offered food pellet.  In fact, only one of the eight bLR-CMS 
rats ate within the fifteen-minute time limit of the test, though there were no significant 
differences in home cage consumption among groups. Home cage food consumption is an 
important control for this particular test and indicates that NSF behavior in the open field is due 
to increased anxiety in bLR-CMS rats, rather than a difference in appetite or food-related reward.   
While feelings of anxiety may be a component of both depression and anxiety disorders, 
the core symptom of anhedonia is unique to depression, [12].  bLR rats show heightened 
anhedonia (reduced sucrose preference) as well as anxiety-like behavior in the NSF compared to 
bHR rats, suggesting that the bLR/bHR model is a model of susceptibility or resilience to 
depression, rather than anxiety disorder per se.  These substantial contrasts in behavior are most 
likely due to the interaction of inborn changes in neurobiology and the stress of the CMS model. 
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There are a number of rat strains available that have been selectively bred for behavioral 
characteristics that may correspond to changes in mood or emotionality. One such strain is the 
Flinders Sensitive Line (FSL), which was originally derived by breeding Sprague Dawley rats 
for altered sensitivity to the acetylcholinesterase inhibitor diisopropyl fluorophosphate. This 
strain was later described as a putative model of depression because the rats exhibit behavioral 
and physiological similarities to depressed patients such as abnormalities in sleep and reduced 
appetite and psychomotor function [144, 145]. However, although the FSL rats share several 
characteristics in common with depression, they lack what many consider a key characteristic:  
anhedonia [144-147].  Interestingly, although both FSL and FRL rats develop signs of anhedonia 
in response to CMS [145, 147] they do not differ from each other in this regard.  Thus, the FSL 
model lacks evidence of a key criterion of depression and the FSL/FRL rats cannot be considered 
a dichotomous model of vulnerability versus resistance to depression.  
Another selectively-bred rat strain was developed by breeding Wistar rats based on either 
high (HAB) or low anxiety-like behavior (LAB) in the elevated plus maze (EPMZ) [148]. The  
heightened anxiety-like behavior in HAB rats extends to other similar behavioral measures of 
anxiety (e.g. light-dark box, [149]) and neurobiological correlates of increased anxiety, such as 
increases in corticotrophin releasing hormone (CRH) in the paraventricular hypothalamus of 
HAB rats, as compared to LAB rats [150]). It has been suggested that HAB rats may be a model 
of depression because of their increased immobility in the forced swim test (FST), a model of 
learned helplessness frequently used to screen for antidepressant drug efficacy[151].  However, 
the FST has proven to be more useful as a tool for drug discovery than as a standalone model of 
depression-like behavior, given that acute SSRI treatment increases active behaviors and 
decreases immobility in unstressed rats [151].  However, measures of anhedonia (e.g., SPT) do 
 35 
not appear to have been reported for HAB rats at baseline and during CMS. Additionally, LAB 
rats show a marked increase in so-called antisocial behavior [149] and aggression [152, 153].  
These findings suggest that the HAB/LAB model may be useful in the study of anxiety and 
social behavior, but, at present, it is difficult to compare HAB/LAB rats to bLR/bHR rats as a 
model of selective vulnerability to depression.  
A different approach to developing animal models of neuropsychiatric disorders has been 
to target specific neurotransmitter systems. For example, a transgenic rat has recently been 
introduced that lacks the serotonin transporter (5-HTT) [154]. These rats, as well as mice lacking 
the 5-HTT, display evidence of increased behavioral anxiety and increased immobility in the 
FST [155-157].  The 5-HTT knockout rat also shows reduced 24-hour sucrose consumption 
[155].  These and other transgenic rodent lines with specific neurochemical alterations may be 
beneficial in determining the role of individual neurotransmitters in depression and have been 
suggested to be useful animal models for research on the mechanisms underlying depression and 
its treatment. 
  In summary, the present study demonstrates that bLR and bHR rats provide a model of 
vulnerability and resistance to depression-like behavior following a period of chronic 
intermittent stress.  This model provides excellent opportunities to further study the interaction of 
genetic predisposition to mood disorders and environmental stress.  Future studies will further 
elucidate the underlying neurobiology associated with these differences in behavior and will 
explore the relationship between depressive behavior and altered autonomic and cardiovascular 
regulation in bLR rats. 
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3.0  VULNERABILITY TO ANHEDONIC BEHAVIOR IS ASSOCIATED WITH 
CARDIOVASCULAR ALTERATIONS IN A RODENT MODEL OF DEPRESSION 
3.1 ABSTRACT 
Major depressive disorder and cardiovascular disease are highly comorbid. We hypothesized that 
rats with vulnerability to depression would also show susceptibility to depression-related 
changes in cardiovascular function.  Male Sprague-Dawley rats that were selectively-bred based 
on either high or low locomotor response to a novel environment were exposed to four weeks of 
Chronic Mild Stress (CMS), a model of depression employing a series of unpredictable, 
intermittent, and variable mild stressors.  We previously showed that bred low-responder (bLR) 
rats are more vulnerable to CMS-induced anhedonia compared to bred high-responder (bHR) 
rats, as measured by preference for a dilute sucrose solution. In the present study, radiotelemetry 
transmitters were implanted to chronically record heart rate (HR) and blood pressure (BP). Heart 
rate variability (HRV) and frequency domain analysis of HRV were calculated as clinically 
relevant measures of autonomic function.  Before CMS began, BP and HR were similar in bLR 
and bHR rats except during the light period (7am-7pm) when BP was higher in bHR rats.  
During the fourth week of CMS, CMS-exposed bLR rats showed increased resting HR, 
decreased HRV, and decreased frequency domain measures related to parasympathetic function, 
in addition to increased cardiovascular reactivity to an acute mild stress.  bLR rats have an 
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increased  inherent sensitivity to CMS-induced depression-like behavior that is associated with 
vulnerability to significant cardiovascular alterations similar to those seen in patients with 
depression.  This study further demonstrates the usefulness of the bLR/bHR model as a robust 
model of susceptibility and resistance to CMS-induced depression and associated cardiovascular 
and autonomic changes.    
3.2 INTRODUCTION 
Major depressive disorder is considered a significant risk factor for coronary heart disease and 
cardiac mortality [2, 3]. This comorbid relationship is independent of common risk factors such 
as increased body mass index, smoking, or preexisting cardiac pathophysiology [3].  Indeed, 
depressed but otherwise healthy patients with no history of cardiovascular disease are as likely to 
suffer an adverse cardiac event as patients with established cardiovascular disease [1, 2].  
Furthermore, this association between depression and cardiovascular disease is bidirectional.  
For example, while approximately 5% of American adults suffer from depression, the prevalence 
of this disorder in patients who have survived a myocardial infarction is several-fold higher [5, 
6].  This bidirectional relationship between depression and cardiovascular disease has been 
firmly established in the clinical and epidemiological literature [6, 10, 37]. 
The relationship between depression and cardiovascular disease has also received support 
from animal research.  Much of this work has utilized one of the best-validated rodent models of 
depression, the depression-like state induced in rats by intermittent unpredictable chronic mild 
stress (CMS) [46, 47, 49-53, 67, 110].  CMS uses a series of mild, unpredictable changes in the 
rodents’ environment to induce a depression-like syndrome. Perhaps the most crucial depression-
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like sign produced by CMS is anhedonia, typically defined in rodents as a reduction in 
preference for sweet solutions [46, 47, 110, 158].  In addition to physiological changes such as 
increases in hypothalamic-pituitary-adrenal (HPA) axis activity and circulating pro-inflammatory 
factors [51, 52], CMS-induced anhedonia is associated with potentially detrimental alterations in 
cardiovascular function that mirror those observed in depressed patients, including increased 
resting heart rate (HR) and reduced HR variability (HRV) [50, 52, 53].  Reduced HRV is used 
clinically as an indicator of risk for cardiovascular disease and heart attack [3, 23, 31], and can 
be attributed to a shift in autonomic drive to the heart, typically reflecting an increase in 
sympathetic activation, a decrease in parasympathetic activation, or both, as reflected by spectral 
analysis of HR rhythm [34, 159]. 
In human patients, the severity of depression is related to the degree of cardiovascular 
disturbance. Reduced HRV and increased resting HR are significantly worse in severely 
depressed patients [21, 33]. Patients with major to severe depression who are otherwise 
medically healthy have twice the mortality risk as those with minor depression [1].   
Furthermore, the risk of cardiac death in patients with coronary artery disease is higher in 
patients with moderate to severe depression and has been shown to persist and even increase in 
the years following hospitalization for coronary artery disease [38].  These findings suggest that 
individuals with increased vulnerability to depression or more severe forms of depression are at 
high risk of cardiovascular disease and cardiac death.   
Recent data from our lab has shown that rats selectively-bred for low locomotor activity 
in a novel environment (bred Low Responder (bLR) rats) are especially vulnerable to 
depression-like behavior [160].  In rodents, low exploratory activity in a novel environment is 
interpreted as a sign of anxiety-like behavior, because rats have an innate aversion to novel, open 
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spaces. Conversely, increased exploration is considered indicative of less anxiety-like behavior.  
bLR rats and their bred-high-responder (bHR) counterparts have been selectively-bred based on 
this behavior, a distinction that has also been observed in behavior across a variety of tests of 
mood and emotionality [71, 76, 161]).  For example, in behavioral tests such as the elevated plus 
maze and light-dark box, bHR rats display significantly less anxiety-like behavior than bLR rats 
[71].  Following exposure to CMS bLR rats show signs of anhedonia, demonstrated by a 
decreased preference for a dilute sucrose solution, more rapidly and to a much greater degree 
than bHR rats.  This apparent vulnerability to CMS in bLR rats and resistance in bHR rats was 
also seen in anxiety-like responses in a novelty-suppressed feeding test [160].  
The current study expands upon these behavioral findings, using cardiovascular data 
recorded from the same group of bHR and bLR rats to examine the comorbid relationship 
between depression and cardiovascular disturbances.  Specifically, we hypothesized that bLR 
rats exposed to CMS would be especially susceptible to the cardiovascular changes that co-occur 
with depression-like behaviors, and that these changes would be more severe in bLR rats than 
bHR rats.  This experiment also permitted an examination of potential differences in baseline 
cardiovascular function and responses to mild stress in bLR and bHR rats.   
3.3 EXPERIMENTAL PROCEDURES 
Animals and Housing  
The present study represents an additional analysis of the bLR and bHR rats for which the 
behavioral consequences of CMS have already been reported [160].  Details of the behavioral 
studies and methods can be found in that report.  As noted in that previous report, the bLR 
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(n=16) and bHR (n=15) rats used in these studies were from the F20 generation bred from 
Sprague-Dawley rats at the Molecular and Behavioral Neuroscience Institute at the University of 
Michigan and shipped to the University of Pittsburgh when they were approximately 3 months 
old (400-450g). At the University of Pittsburgh the rats were housed singly in plastic tubs under 
controlled environmental conditions with a 12/12 light dark cycle (lights on at 7 am).  Food 
(Purina Chow) and tap water were available ad libitum except as noted as a part of CMS and 
testing procedures. All animal protocols conform with the NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the University of Pittsburgh Animal Care and Use 
Committee.  
 
Telemetry transmitter implantation 
After one week to acclimate to the housing facility at the University of Pittsburgh, telemetry 
transmitters (PA-C40, Data Sciences International) were implanted in all rats to record BP, HR, 
and HRV.  Under isofluorane anesthesia (2% in 100% oxygen, delivered at 1-1.5 L/min), the 
body of the transmitter was anchored to the abdominal muscle in the intraperitoneal space and 
the catheter was implanted into the femoral artery.  Wounds were closed with silk suture and 
Ketoprofen (2mg/kg, s.c.) was administered as an analgesic.  Rats were allowed 7-10 days to 
recover before baseline recordings began.   
 
Chronic Mild Stress Protocol 
After a two-week period to collect baseline measurements, rats were either exposed to CMS for a 
total of 5 weeks, or were handled according to standard animal care practices (Control group).  
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An example of the CMS schedule is shown in Figure 4 (p.19)  and details of the CMS protocol 
are described in our previous publication [160]. 
 
Sucrose Preference Test   
Anhedonic behavior was assessed in rats at weekly intervals using a sucrose preference test 
(SPT).  The testing methods and results have been reported in detail in Stedenfeld et al. [160] 
(Chapter 2).   
 
Radiotelemetry Data Collection & Analysis 
BP and HR measurements were collected using Dataquest ART 4.0 software (Data Sciences 
International) as a 10-second average every 2 minutes for the majority of the experiment. 
Continuous, beat-by-beat recordings of pulsatile BP were also made at selected points in the 
study in order to calculate HRV and components of its power spectrum.  Due to hardware 
limitations, continuous recordings for HRV were taken from only 8 rats at a time, of the same 
treatment group (ie, CMS or Control), with 4 rats from each strain. HRV values are from the 
same time of day, but different days during the same week of the experiment.  CMS was 
continued during recordings; therefore, recordings from CMS-exposed rats were sometimes 
taken during exposure to various ongoing stressors, including exposure to strobe light or white 
noise, water deprivation, and paired housing.   
The telemetry transmitter also recorded activity level on the same schedule as BP and 
HR.  The PA-C40 telemetry transmitter model records activity based on changes in transmitter 
signal strength, providing a crude index of overall activity. 
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HRV analysis was focused on the dark period, when rats are typically more active.  
Values from the first quarter of the dark period (time: 7pm – 10pm), when rats had a large 
increase in activity (data not shown) were evaluated, as were values from the third quarter of the 
dark period (1am – 3am).  Time-domain HRV was calculated from continuous recordings of 
pulsatile BP, as the standard deviation of inter-beat-intervals (IBIs) within each of these two 
three-hour segments.   
To assess autonomic contributions to HRV, frequency components of HRV were 
analyzed using the custom open source HRV analysis program, Physioscripts, which employs a 
band limited variance technique  [34].  The sequence of IBIs was resampled at 10 Hz to create a 
regularly spaced time series. In addition to applying thresholds and limits to eliminate artifacts, 
sequences were also visually inspected for artifact, and missing or excluded points were replaced 
by linear interpolation.  A bandpass filter was applied across the frequency band of interest 
before calculating the variance of the filtered time series.  Boundaries for the frequency bands 
were selected based on previous studies in rats [162, 163]:  total power (TP) 0-5 Hz,  high 
frequency (HF) 1-3 Hz, low frequency (LF) 0.04-1.0 Hz, and very low frequency (VLF) 0-0.39 
Hz.  Frequency distribution analysis using this technique produces results analogous to spectral 
analysis using Fourier transform [22], but provides more robust results due to the filtering 
technique used, which omits frequencies outside of the specified bands [159].   
 
Cage switch stress   
Cage switch stress was used to assess cardiovascular reactivity to an acute mild stressor.  During 
week 5 of CMS, HR and BP were continuously recorded for 50 minutes during the weekly cage 
change, in which the rat was transferred from a cage with week-old soiled bedding to a clean 
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cage with fresh bedding.  This occurred during the light cycle, between 10:00am and 12:00pm; a 
similar cage transfer occurred once per week to all animals during the 8 weeks they were housed 
at the University of Pittsburgh.  
 
Data Analysis 
Statistical analyses were performed using Microsoft Excel and PASW Statistics 18.0 (SPSS).  
Values are expressed as mean ± SEM.  For comparisons of four groups, 2-way ANOVA (Strain 
x Treatment) was used, with Tukey HSD post-hoc tests where appropriate. Repeated measures 
ANOVA was used to identify significant differences across time, with Tukey HSD test as 
appropriate. For all tests, a two-tailed p-value of 0.05 or less was considered significant.  
3.4 RESULTS 
Sucrose Preference Test  
As we reported previously [160], CMS-exposed and control groups of both strains showed a 
robust preference for sucrose during the baseline period before CMS was started.  During week 2 
of CMS, CMS-exposed bLR rats showed a significantly reduced sucrose preference (compared 
to their baseline control, as well as the bLR-Control group and both bHR groups). This persisted 
throughout the remainder of the experiment.  In contrast, the bHR showed a mildly reduced 
sucrose preference only after 4 weeks of CMS. 
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Baseline cardiovascular measurements in bHR and bLR rats 
At baseline, before CMS began, values for HR and BP during the light and dark period were 
within the typical range for adult Sprague-Dawley rats (Figure 8A-D) and showed a clear 
circadian pattern. Baseline HR values did not significantly differ between bLR and bHR rats 
during the light or dark period, though they tended to be higher in bHR rats.  bHR rats had 
significantly higher resting BP than bLR rats during the dark period (p<0.05), but not the light 
period.  Baseline HRV values were not significantly different. Activity, assessed by changes in 
telemetry signal strength as the rat moves about its cage, showed a strong circadian pattern, with 
increased activity during the dark phase.  As expected and reported previously [71, 81, 160], 
bHR rats were more active across the 24-hour period than bLR rats (p=0.003, data not shown).  
 
Heart rate and blood pressure during CMS exposure 
HR was significantly elevated in bLR-CMS rats compared to bLR-Control and bHR-CMS rats 
during the dark phase of weeks 3 and 4 of CMS (Figure 8A, p < 0.05). There were no significant 
differences in HR during the light period during any week of CMS (Figure 8B).  There were also 
no significant differences in BP between CMS-exposed and control groups at any time point 
(Figure 8C & 8D). However, bHR rats had significantly higher BP than bLR rats during the 
light period of CMS week 4 (Figure 8D, p=0.003); this effect was mainly driven by the 
significant difference between the bHR-Control group, and the bLR-Control group (p=0.05).   
Additionally, the difference between light-period and dark-period HR and BP values did not 
change significantly over the four weeks of CMS, suggesting that cardiovascular circadian 
rhythms remained intact.  Circadian rhythms in activity were also intact for all groups and there 
 45 
were no significant differences in 24-hour activity between CMS-exposed and Control rats of 
either strain (data not shown).  
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Figure 8: 24-hour resting heart rate and blood pressure 
HR and BP were recorded chronically throughout the experiment, across the dark period (7pm-7am) and 
the light period (7am-7pm). HR during the dark phase was elevated in bLR-CMS rats during weeks 3 and 
4 of CMS (Fig 8A).  There were no significant differences in HR during the light phase (Fig 8B), BP 
during the dark phase (Fig 8C), or BP during the light phase (Fig 8D). Values are means  SEM; 
n=8/group except bHR-Ctrl, n=7.  *:p<0.05 compared to Controls. 
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Cardiovascular response to CMS protocol stressors 
BP and HR were recorded throughout the CMS protocol, allowing for analysis of the impact of 
the various stressors on these parameters. However, during continuous overnight recordings of 
beat-by-beat data for HRV analysis only 8 rats could be recorded at one time. Therefore, this 
data set was not entirely comprehensive, but includes cardiovascular data from smaller groups of 
rats during a subset of stressors. We have chosen to present data from a few of these stressors as 
representative examples of cardiovascular responses to a range of CMS stressors.  The following 
stressors were chosen because recordings were available for both bLR-CMS and bHR-CMS rats 
for at least two of the four weeks of CMS: overnight wet bedding plus paired housing, strobe 
light, and loud white noise.  The combination of overnight wet bedding and paired housing 
produced the largest and most sustained HR response (Table 2, Figure 9A).  During this weekly 
stressor, CMS-exposed bHR (n=4) and bLR rats (n=4) were paired with another CMS-exposed 
rat of either the same or opposite strain.  The same eight rats remained in their home cage and 
were recorded from each week and were always paired with an unfamiliar rat of similar body 
weight whose transmitter was turned off. Once the intruder rat was placed in the cage, 300-
500mL of lukewarm water was poured on the bedding, often wetting the rats as well.  Aggressive 
behavior was sometimes observed in the first 30-60 minutes of paired housing, but was never 
sustained or severe enough to require separation.  Following onset of the stressor, all rats had a 
significant increase in HR and BP (Figure 9A).  There were no significant differences in peak 
HR response between bHR and bLR rats in any of the 4 weeks of CMS (Table 2).  Peak 
response was defined as the difference between the highest recorded value in the 15 minutes 
following stressor onset and at t = -10 minutes.  During each of the four weeks of CMS, bLR-
CMS rats had a more sustained HR response than bHR-CMS rats, as measured by a larger area 
 48 
under the curve (AUC), for the first 240 minutes (4 hours) of stress (p<0.01, Table 2).  There 
were no significant differences between bLR-CMS and bHR-CMS rats in peak BP response or 
AUC during any of the 4 weeks of CMS.    
Most stressors used in the CMS protocol, however, did not produce large cardiovascular 
responses.  For example, a strobe light turned on during the dark period elicited a very small 
increase in HR and BP (Figure 9B). Peak HR response and AUC were not significantly different 
between bLR-CMS and bHR-CMS rats.  Similarly, loud (85dB) white noise caused a small and 
transient increase in HR and BP (Figure 9C).  The peak HR response to white noise was 
significantly larger and more sustained in bLR-CMS rats than bHR-CMS rats during CMS week 
2 (p<0.01, Table 2).  For both of these stressors, there were no significant differences in peak BP 
response or AUC for BP response between bLR-CMS and bHR-CMS rats.  These data 
demonstrate that the CMS protocol produced small to moderate increases in HR and BP, and that 
these changes were sometimes larger or more sustained in bLR rats than bHR rats.   
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Figure 9: Heart rate responses 
to three CMS stressors during 
CMS week 4 
9A: HR response to Paired 
housing plus wet bedding. CMS 
rats were paired overnight in a 
cage with dampened bedding. 
There was no significant 
difference in peak HR response, 
but bLR-CMS rats had a longer 
duration of HR response, 
measured by AUC (p<0.01).  
9B: HR response to Strobe light 
during the dark period. There 
were no significant differences in 
peak response or duration.  
9C: HR response to white noise. 
There were no significant 
differences in peak response or 
duration.  
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Table 2: Peak and duration of heart rate and blood pressure responses to three CMS stressors 
 
Peak increase and area under the curve (AUC) were calculated for HR and BP responses to each of three CMS stressors:  paired 
housing plus wet bedding, strobe light, and white noise. Repeated measures ANOVA yielded no significant effects for any of these 
measures. Values are means  SEM. #p<0.01 compared to opposite strain (one-way ANOVA).   
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Heart Rate Variability 
Time-domain HRV (s.d. of the IBI) was measured each week throughout the CMS period.  
Analysis of HRV focused on the dark period, when rats are more active, and for which we have 
lengthy continuous cardiovascular recordings.  During the first quarter of the dark period, there 
was a significant overall effect of strain (p=0.03) and stress (p=0.006), as well as a significant 
interaction of time and stress (p=0.05) (Figure 10).  Baseline (pre-CMS) values are not included 
in this analysis because they were not recorded across the dark period; however, as noted above, 
baseline HRV values were not significantly different among groups (data not shown).  There 
were also no significant differences among groups during weeks 1-3 of CMS.  During CMS 
week 4, bLR-CMS rats had significantly reduced HRV compared to bLR-Control (p<0.01) and 
bHR-CMS (p<0.05) groups (Figure 10).  bHR-CMS rats also had reduced HRV compared to 
their controls (p<0.01).  
Frequency domain analysis of HRV was performed to evaluate possible sources of the 
reduction in HRV.  During the fourth week of CMS, both bLR-CMS and bHR-CMS rats had 
reduced total power compared to unstressed controls (p<0.05, Figure 11A).  bLR-CMS rats had 
a significant reduction in HF power (Figure 11B) compared to controls (p<0.05), and bLR rats 
had lower LF power than bHR rats (p<0.05), regardless of whether they were exposed to CMS or 
not (Figure 11B).  Both bLR-CMS and bHR-CMS rats had reduced VLF power, compared to 
unstressed controls (p<0.05, Figure 11D).   
Interestingly, this significant reduction in HRV in bLR-CMS and bHR-CMS rats was not 
evident across the entire dark period. During the third quarter of the dark period (0100 – 0400), 
for instance, there was not a significant difference in HRV during the fourth week of CMS 
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(Table 3).  Furthermore, there were no significant differences in frequency domain components 
of HRV, with the exception of an increase in LF power in bHR-CMS rats (p<0.01, Table 3).  
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Figure 10: Time-domain HRV in bHR/bLR rats across four weeks of CMS 
HRV was measured during the first quarter of the dark period (7pm-10pm). A repeated measures 
ANOVA yielded a significant effect of Strain (p=0.03), Stress (p=0.006) and a significant interaction of 
Stress x Time (p=0.05).  HRV was significantly reduced in bLR-CMS rats compared to bLR-Control rats 
(p<0.01) and bHR-CMS rats (p<0.05).  bHR-CMS rats also had reduced HRV during the fourth week of 
CMS. Values are means  SEM.  *:p<0.01 compared to Controls; #:p<0.05 compared to opposite strain. 
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Figure 11: Frequency domain components of HRV, final quarter of the dark period 
To assess autonomic contributions to HRV, frequency domain components were also calculated during 
the first quarter of the dark period. 11A: Total Power (0-5Hz), 11B: high frequency power (HF, 1-3Hz), 
11C: low frequency power (LF, 0.04-1.0 Hz), 11D: very low frequency (VLF, 0-0.39 Hz). Values are 
means  SEM. *:p<0.05 compared to Controls; #:p<0.05 compared to opposite strain.  
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Table 3: Frequency domain components of HRV, third quarter of the dark period 
 
Values are means  SEM. *:p<0.01 compared to Controls; #:p<0.01 compared to opposite strain.  
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Cardiovascular reactivity to an acute novel stress 
During Week 5 of CMS, HR and BP were monitored during an acute stress to evaluate 
cardiovascular reactivity. Baseline BP and HR were recorded 10 minutes before being placed in 
a cage with clean bedding.  All groups were within the normal range for Sprague-Dawley rats at 
rest.  Just before the cage change there was a significant baseline effect of CMS for both HR and 
BP, which was mainly due to a significant difference in HR (p=0.03) and BP (p=0.04) between 
bHR-Control rats and bLR-CMS rats; there were no other significant differences among groups 
at baseline.  
Immediately following placement in a cage with clean bedding, all groups showed a 
significant increase from baseline in both HR and BP (Figures 12A & 12C).  Both strains of 
CMS-exposed rats had significantly higher peak increases in BP compared to controls (p < 0.05; 
Figure 12D).  bLR-CMS rats had a significantly larger peak increase in HR compared to bHR-
CMS rats (p = 0.02) and both control groups (p = 0.004; Figure 12B).  There was also a 
significant main neffect of stress on the area under the curve (AUC) of cardiovascular responses 
during the first 40 minutes following stressor onset (i.e., t=0-40).  AUC for HR (Figure 13A) 
and BP (Figure 13B) responses to novel cage placement was higher in bLR-CMS rats compared 
to bLR-Control rats (one-tailed ANOVA, p = 0.02 and p = 0.03, respectively).  Additionally, 
there was a significant main effect of stress on the duration of the HR and BP responses (one-
tailed ANOVA, p = 0.05 and p = 0.04, respectively). bLR-CMS rats had HR and BP responses 
that remained elevated above baseline for significantly longer than bLR-Control rats (BP: bLR-
CMS: 41±7min vs. bLR-Control: 22±3min, p=0.03; HR: bLR-CMS: 49±7min vs. bLR-Control: 
27±5min, p=0.02). This relationship was not observed in bHR rats (BP: bHR-CMS: 30±4 vs. 
bHR-Control 28±8, p=0.40; HR: bHR-CMS: 42±9 vs. bHR-Control 43±15, p=0.48).   
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Figure 12: Increases in HR and BP in response to a novel cage stress in bHR/bLR rats 
HR and BP increases from baseline after rats were transferred to a new cage with clean bedding. Values 
are means ± SEM. n=8/group, except bHR-Control, which had n=7 and two recordings from this group 
were not usable, thus n=5. *: p<0.01 compared to Controls; #p<0.01 compared to opposite strain. 12A: 
bLR-CMS rats had the largest peak increase in heart rate. Baseline heart rate (bpm); t = -10 minutes: 
bHR-Ctrl: 329±17, bHR-CMS: 291±12, bLR-Ctrl: 317±20, bLR-CMS: 268±7. 12B: Bar graph of peak 
increase in heart rate from baseline 5 minutes after cage switch was performed.  12C: Both strains of 
CMS-exposed rats had significantly higher peak blood pressure responses compared to controls. Baseline 
blood pressure (mmHg), t = -10 minutes: bHR-Ctrl: 104±4, bHR-CMS: 95±3, bLR-Ctrl: 99±4, bLR-
CMS:  92±1 (significant effect of treatment, p<0.05).  12D: Bar graph of peak increase in blood pressure 
from baseline 10 minutes after cage switch was performed. 
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Figure 13: Duration of the increase in HR and BP in response to a novel cage stress 
13A: Bar graph of area under the curve (AUC) for heart rate response to cage switch.  
13B: Bar graph of area under the curve (AUC) for blood pressure response to cage switch 
Values are means ± SEM. n=8/group, except bHR-Control, which had n=7 and two recordings from this 
group were not usable, thus n=5. *:p<0.05 vs. Controls of same strain.  
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3.5 DISCUSSION 
This chapter presents evidence that vulnerability to chronic stress-induced depressive behavior is 
associated with alterations in cardiovascular function. These changes include increased resting 
HR, reduced HRV, reduced frequency domain power, and increased cardiovascular reactivity to 
acute stress. Behavioral data from the rats used in the current study were featured in a previously 
published report [160] that demonstrated increased vulnerability of bLR rats to CMS-induced 
depressive behavior compared to bHR rats. These two selectively-bred strains of Sprague 
Dawley rats were bred based on their low and high locomotor responses to a novel environment, 
a behavioral phenotype that appears to correspond with similarly divergent behavior in tests of 
mood and anxiety-like behavior [71, 81].  When bHR and bLR rats were exposed to CMS, bLR-
CMS rats showed decreased preference for sucrose compared to bHR-CMS rats, bLR-Control 
(unexposed) rats, and their own pre-stress baselines beginning in the second week of CMS.  This 
anhedonic behavior persisted throughout the experiment in bLR-CMS rats, but was not observed 
in bHR-CMS rats until the final week, and even then was less robust, suggesting that bLR and 
bHR rats provide an excellent model in which to study the interaction of environmental stress 
and heritable predisposition to depression.   
 
Baseline differences between bLR and bHR rats 
The current study expands on previous behavioral findings in bLR and bHR rats by incorporating 
cardiovascular parameters that were chronically recorded throughout the CMS period.  We first 
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examined whether inherent behavioral differences in locomotion and emotionality in bLR and 
bHR rats extended to differences in cardiovascular function during the baseline period before 
CMS began.  Though bHR rats tended to have higher HR and BP than bLR rats during both the 
dark and the light periods, this relationship only reached significance when comparing BP during 
the dark period.  In addition, there were no significant differences in HRV at baseline.  
By definition, bHR rats have a higher locomotor response to a novel environment ([71, 
81, 123, 124, 160, 161].  This increase in locomotion was also apparent in 24-hour home cage 
activity, as assessed by telemetry transmitter signal strength. During the baseline period, bHR 
rats were significantly more active than bLR rats.  Interestingly, when cardiovascular reactivity 
to cage change was measured during Week 5 of CMS, bHR-Control rats tended to have longer 
BP and HR responses than bHR-CMS rats, as quantified by AUC. Though this difference did not 
reach statistical significance, bHR rats’ extended cardiovascular response may be due in part to 
their inherent heightened locomotor response to a novel cage, and reduced cardiovascular 
response in bHR-CMS rats may suggest that CMS blunts the acute locomotor  response to 
novelty, even though 24-hour activity level is not different between strains.  
 
CMS alters cardiovascular function 
Previous studies using CMS have found significant changes in cardiovascular function that 
mirror those observed in human patients with cardiovascular disease [49, 50, 52, 53].  We 
hypothesized that bLR-CMS rats, which are especially sensitive to depression-like behavior 
brought on by CMS exposure, would also have an increased sensitivity to CMS-associated 
cardiovascular changes.  Indeed, there was a significant increase in resting HR during the dark 
period in the bLR-CMS group compared to bHR-CMS and control groups during CMS weeks 3 
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and 4.  No such increase in HR was observed during the light period (0700-1900), and no 
significant differences were seen in BP during any week, either during the dark or light period.  
Previous studies have reported a similar elevation in HR recorded during the light period at the 
end of a four week period of CMS [49, 50, 52, 53] and elevated resting HR is frequently 
observed in depressed patients throughout the light-dark cycle [164-166]. 
The CMS model was developed to mimic the types of daily stressors that, over time, 
result in depression-like signs [46].  The stressors used include changes to the animals’ 
environment, such as overnight lighting and water deprivation, and are assumed to be relatively 
mild.  Despite the frequent use of the CMS model, to our knowledge there has not been a report 
of the physiological or autonomic impact of individual intermittent mild stressors. Because HR 
and BP were monitored chronically throughout this experiment, we were able to record 
cardiovascular responses to many of these stressors, and have analyzed data from strobe light, 
white noise, and the combination of wet bedding and paired housing.  Overall, stressors 
produced small to moderate increases in BP and HR, with the largest increases being in response 
to paired housing combined with wet bedding. Though there were no significant differences in 
peak HR or BP response between bLR and bHR rats, the HR response was prolonged in bLR-
CMS rat, as measured by area under the curve once depression-like behaviors have emerged.  
More typical were the small increases in HR and BP in response to strobe light and loud white 
noise.  bHR and bLR rats did not differ in their response to strobe light turned on during the dark 
period. bLR rats had higher peak and longer HR responses to white noise during week 2 of CMS, 
but not during week 4, suggesting that this group may have adapted to the stressor.   It is possible 
that the longer duration of HR response to some stressors in bLR-CMS rats may be indicative of 
an underlying difference in sensitivity to stress in bLR rats. As cardiovascular reactivity to these 
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stressors is only one component of autonomic responses to stress, further studies employing 
measurements of HPA reactivity such as plasma corticosterone or other circulating factors such 
as cytokines across the 4 weeks of CMS would further clarify this issue. 
 
CMS enhances cardiovascular reactivity to acute stress 
The depression-like changes in bLR rats’ behavior were also associated with an increase in 
cardiovascular reactivity to acute stress, as measured by an increase in HR and BP in response to 
a novel cage. Notably, the stressor used, switching to a clean cage, is a procedure that occurs 
each week to all rats as their cages are cleaned. Despite the assumed familiarity of this 
procedure, bLR-CMS rats had a larger increase in HR than either bHR-CMS or control groups.  
This difference between bLR-CMS and bHR-CMS reactivity appears to be specific to the 
autonomic regulation of the heart, as both bHR-CMS and bLR-CMS rats had similar BP 
responses to the cage change, compared to control groups.  Additionally, AUC of the HR and BP 
response to stress was significantly higher in bLR-CMS than bLR-Control rats, and HR and BP 
remained elevated longer in bLR-CMS rats; however, this relationship was not observed in bHR 
rats. This increased magnitude of cardiovascular response may be further evidence of the 
considerable effect of CMS on bLR rats.  Baseline BP and HR values just prior to the cage 
switch test were slightly lower in the rats exposed to CMS, though such differences were not 
observed when BP or HR were monitored over longer periods of time.    
 
CMS reduces heart rate variability  
In addition to the CMS-induced increase in resting HR and heightened cardiovascular reactivity, 
HRV was significantly reduced in both bHR-CMS and bLR-CMS animals during the fourth 
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week of CMS.  Additionally, HRV was significantly lower in bLR-CMS rats than bHR-CMS 
rats.  Thus, the group that had the greatest degree of anhedonia [160], also had the most reduced 
HRV. This association of a large reduction in sucrose preference and substantially reduced HRV 
in bLR rats closely mirrors the correlative relationship between severity of depression and 
reductions in HRV apparent in depressed patients [21, 33].   
Reduced HRV is a critical risk factor for cardiac mortality and likely reflects a disruption 
in sympathovagal balance to the heart. Reduced HRV in the time domain (s.d. of IBI), can 
represent an increase in sympathetic activity, a decrease in parasympathetic activity, or both.  
Frequency domain or spectral analysis of HRV is often used in both experimental and clinical 
studies as a noninvasive method of assessing autonomic contributions to a global reduction in 
HRV.   Total power across the frequency spectrum is related to overall autonomic balance 
whereas the HF band corresponds to the respiratory frequency, and is used as an index of vagal 
or parasympathetic influence on HRV.  LF HRV appears to be influenced by both sympathetic 
and parasympathetic elements [22, 35] and VLF power may reflect cardiovascular modulation by 
the renin-angiotensin system [29, 35, 36] or its effects on parasympathetic influence on the heart. 
Frequency domain analysis of HRV during the fourth week of CMS revealed that bLR-CMS rats 
had reduced total power, HF, and VLF compared to bLR-Control rats (p<0.05). Reduced HF 
power has been observed in both clinical [43] and experimental studies [167] of cardiovascular 
dysfunction associated with depressive symptoms, and likely reflect a decrease in vagal control 
of the SA node [168]. Reductions in total power and VLF are most strongly associated with 
mortality after myocardial infarction, even more so than HF or LF [24], and account for nearly 
30% of the risk conferred on cardiac mortality by depression [31], making it one of the most 
reliable measurements of mortality risk. Taken together, these data suggest that the large 
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reduction in frequency-domain components of HRV seen in bLR-CMS rats may be due to a 
decrease in parasympathetic control of the heart mirroring the clinical findings of HRV 
alterations associated with depression. 
Interestingly, this reduction in HRV was not apparent across the entire dark period. For 
example, when the same HRV analysis was performed during the third quarter of the dark period 
(0100 – 0400), a period less influenced by changes in the light cycle, there were no significant 
differences in HRV or its frequency domain components, with the exception of bHR-CMS LF 
power (Table 3).  Experimental studies that measure HRV in animals typically do so acutely, 
upon termination of the experiment, and only for 5- 20 minutes.  This is an appropriate analysis 
method, and, indeed, 20 minutes is the recording length recommended by the Task Force of The 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology in the prominent article that discusses this method [22].  However, our results 
suggest that longer recording periods, which may be more comparable to human studies using 
Holter recordings, likely yield more complex results than short recording periods.  Even in the 
case of animals with extreme anhedonia and greatly reduced HRV, as in the current study, 
reduced HRV is not apparent at every time period.   
Decreased HRV has been reported in various animal models of depression.  A series of 
studies by Grippo et al used CMS to induce anhedonia in rats and demonstrated reduced HRV 
following 4 weeks of CMS [49, 50, 52, 53, 68].  Similar findings have been reported in studies 
using social isolation to induce anhedonia in the monogamous prairie vole (for a review, see 
[158]). After a 4 week period of isolation from their housing partner, both time-domain HRV  
and HF power (in this case measured by respiratory sinus arrhythmia) were reduced in both male 
and female prairie voles [167]).  HRV was also reduced in the Flinders Sensitive Line (FSL) rat 
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[169], a strain of rat originally bred for its thermoregulatory sensitivity to cholinergic drugs that 
has also been shown to be susceptible to depression-like behavior [144].  However, this 
alteration may be due to physiological changes that are unrelated to the depression-like behavior 
of the FSL rat, as HRV was also reduced in the Flinders Resistant Line (FRL) rat, and there was 
no significant difference between FSL and FRL rats.  Furthermore, HRV measurements were 
taken acutely, under urethane anesthesia, which makes them difficult to compare to chronic 
measures in conscious rats.   
In conclusion, vulnerability to CMS-induced depression-like behavior also confers a 
vulnerability to significant cardiovascular alterations associated with human depression. These 
include increased resting HR, reduced HRV, changes in frequency domain components of HRV, 
and increased cardiovascular reactivity. Frequency-domain analysis of HRV suggests that these 
alterations may be due in part to a decrease in parasympathetic function. This robust model of 
susceptibility and resistance to CMS-induced depression and associated cardiovascular changes 
should provide a powerful approach to examining the mechanisms underlying this association 
and potential therapeutic interventions for treating these serious comorbid conditions.    
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4.0  CANDESARTAN REVERSES ANHEDONIA AND CARDIOASCULAR 
ALTERATIONS IN A RODENT MODEL OF DEPRESSION 
4.1 ABSTRACT 
Major depressive disorder and cardiovascular disease share a comorbid bidirectional 
relationship, wherein the presence of one increases the likelihood of the other.  Antidepressants 
such as selective serotonin reuptake inhibitors (SSRIs), might not improve cardiovascular 
mortality, even when depressive signs are ameliorated.  Candesartan, an AT1R antagonist often 
prescribed for hypertension and other cardiovascular disorders, has been shown to be anxiolytic 
in animal models, and may have antidepressant properties.  This study used adult male rats that 
were selectively-bred for low locomotor response to a novel environment, which are especially 
vulnerable to chronic mild stress (CMS) -induced signs of depression and associated 
cardiovascular changes.  Rats were exposed to CMS for five weeks, which induced anhedonia 
and decreased heart rate variability (HRV) and frequency-domain components of HRV, 
clinically relevant markers of risk for cardiac death; control rats were housed under standard 
conditions.  During the sixth week of the experiment, rats were implanted with subcutaneous 
osmotic minipumps containing candesartan, the SSRI fluoxetine, or vehicle, and CMS or control 
housing was continued for an additional four weeks.  Candesartan rapidly reversed anhedonic 
behavior measured by sucrose preference during the first week of treatment.  Candesartan also 
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reduced CMS-induced anxiety-like behavior in the novelty-suppressed feeding test, and had 
positive effects in the forced swim test in unstressed rats.  Furthermore, candesartan reversed the 
CMS-induced reduction in HRV and its frequency domain components.  Although fluoxetine 
also reversed anhedonic and anxiety-like behavior, and had positive results in the FST, it did not 
reverse the reduction in HRV and even decreased HRV in control (unstressed) rats.  These 
results provide robust evidence that candesartan is a novel, effective treatment for comorbid 
depression and cardiovascular disease.  
4.2 INTRODUCTION 
Major depressive disorder and cardiovascular disease are highly comorbid, and the presence of 
one disorder increases the likelihood of the other.  Depression is an independent risk factor for 
coronary heart disease both in patients with cardiovascular disease as well as medically healthy 
individuals [1, 38, 39, 44, 170] and is a significant independent predictor of mortality within 18 
months following a heart attack [2, 4]. Frasure-Smith and colleagues [2] found that in the six 
months following a myocardial infarction, mortality was 3.5 times higher in patients who were 
also depressed than those who were not. 
Animal models of depression have been extremely useful in providing support for this 
relationship between depression and cardiovascular disease and establishing an experimental 
model in which to study possible underlying mechanisms and methods of treatment. For 
instance, the chronic mild stress (CMS) model of depression in rodents, which uses a series of 
intermittent unpredictable mild stressors to induce an anhedonic state [46, 47], also incorporates 
many of the cardiovascular disturbances associated with human depression, including increased 
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resting heart rate (HR) and decreased HR variability (HRV).  Decreased HRV is a risk marker 
for heart attack and cardiovascular mortality [23, 31, 40], and more severe signs of depression 
are associated with larger reductions in HRV [21, 33].  
Recent studies from our lab have shown that rats selectively-bred for reduced locomotor 
behavior in a novel environment (bred low responder or bLR rats) are especially vulnerable to 
the anhedonic effects of CMS [160] and that depression-like behaviors in these animals were 
also associated with changes in cardiovascular function, including decreased HRV, and 
decreased very low frequency power of HRV, a component of frequency-domain analysis that 
corresponds to parasympathetic activity and is a predictor of cardiac mortality [3, 31].  Bred high 
responder (bHR) rats, on the other hand, were resistant to anhedonia, and had only modest 
reductions in HRV.   
There are conflicting reports regarding whether antidepressant therapy improves reduced 
HRV or risk for cardiac mortality. Tricyclic antidepressants have known cardiotoxic properties 
and may exacerbate existing cardiovascular conditions [82-84], and their use in patients with 
cardiovascular disease has been discouraged [85, 86].  While some studies indicate that selective 
serotonin reuptake inhibitors (SSRIs) improve cardiovascular outcomes [19, 87], others find that 
SSRIs do not improve mortality risk, even when depression is in remission [88]. Still other 
studies report that SSRIs may worsen outcomes, especially when administered in conjunction 
with beta-blockers, which are commonly prescribed for various cardiovascular disorders [89].  In 
rats exposed to 4 weeks of CMS, simultaneous treatment with the SSRI fluoxetine prevented the 
anhedonic effects of CMS, but did not fully prevent the reduction in HRV [53].   
The renin angiotensin system (RAS) has an established role in cardiovascular regulation, 
and drugs that inhibit the RAS such as AT1R blockers (ARBs) and angiotensin converting 
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enzyme (ACE) inhibitors have been shown to reduce mortality from heart failure [95], possibly 
by reversing the reduction in VLF mentioned above [29, 35, 36]. The RAS also plays a key role 
in the physiological response to acute and chronic stress in studies in rodents.  Chronic 
pretreatment with an ARB reduces anxious behavior in tests such as the elevated plus maze 
[101], attenuates the hypothalamic pituitary adrenal (HPA) axis response to an acute stress [100] 
and prevents gastric ulceration associated with a chronic stress [102, 103]. Furthermore, drugs 
that inhibit the RAS may have antidepressant properties.  The ARB losartan and the ACE 
inhibitor captopril both give positive antidepressant-like effects in the forced swim test in mice 
[107, 108], a supposed animal model of despair behavior.  There is some evidence indicating that 
ACE inhibitors improve mood and cognitive function in hypertensive patients [104],  and 
antidepressant use is lower in hypertensive patients taking ARBs or ACE inhibitors [106].   
The current study investigates the potential antidepressant effects of the ARB candesartan 
on CMS-induced changes in behavior and cardiovascular function.  These experiments were 
performed in bLR rats, which are especially vulnerable to depression-like behavior [160], and 
were compared with the effects of the SSRI fluoxetine.  We hypothesized that candesartan would 
reverse CMS-induced anhedonia and the reduction in HRV and its power spectral components, 
possibly more effectively than fluoxetine.   
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4.3 EXPERIMENTAL PROCEDURES 
Animals and Housing 
Adult male bred low responder (bLR) rats were selectively-bred from a Sprague Dawley line at 
the Molecular and Behavioral Neuroscience Institute at the University of Michigan and shipped 
to the University of Pittsburgh when they were approximately 2 months old (250-300g).  This 
experiment used 48 bLR rats that were singly housed in plastic bins with wire lids.  CMS-
exposed and control rats were housed in separate adjacent rooms under similar conditions. The 
housing rooms were kept at a controlled temperature and humidity on a 12:12 light-dark cycle 
with lights on at 7:00 am. Food (Purina Chow) and tap water were available ad libitum except 
where noted as a part of the CMS protocol or testing procedures.  Body weight was measured 
weekly for the duration of the experiment.  All animal protocols conform to the NIH Guide for 
the Care and Use of Laboratory Animals and were approved by the University of Pittsburgh 
Animal Care and Use Committee.  Figure 14A shows an outline of the experimental procedures.  
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Figure 14: Diagram of experimental procedures and typical CMS schedule 
Figure 14A: Rats were implanted with telemetry transmitters and allowed 7-10 days to recover. After a 
baseline recording period, rats were exposed to control conditions or CMS for a total of 9 weeks.  Drugs 
were administered via subcutaneous osmotic minipump beginning in week 6. The novelty-suppressed 
feeding test (NSF) was administered in weeks 5 and 9 and the forced swim test (FST) was administered in 
week 8.  Figure 14B: Rats were exposed to either 9 weeks of intermittent unpredictable stressors or 
control conditions.  Control rats were housed in separate rooms and handled according to usual animal 
care protocols with the addition of a weekly sucrose preference test (SPT).  
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Telemetry transmitter implantation surgery 
Rats were left undisturbed for one week after arriving at the animal facility at the University of 
Pittsburgh. After this time, telemetry transmitters (PA-C40, Data Sciences International) were 
implanted in a subset (n=30) of the rats to record blood pressure (BP), heart rate (HR), and HR 
variability (HRV); the remaining rats (n=18) were not implanted with transmitters (due to limited 
availability of transmitters for this experiment). Under isoflurane anesthesia (2% in 100% 
oxygen, delivered at 1-1.5 L/min), the body of the transmitter was anchored to the abdominal 
muscle in the intraperitoneal space and the catheter was implanted into the femoral artery.  
Wounds were closed with silk suture and a single dose of Ketoprofen (2mg/kg, s.c.) was 
administered as an analgesic.  Rats were allowed 7-10 days to recover from surgery before 
baseline recordings began.   
 
Chronic Mild Stress protocol 
Baseline cardiovascular and sucrose preference data (see below) were collected for two weeks 
before CMS began.  Rats were either exposed to CMS (n=24) or were handled according to 
standard animal care procedures (Control group, n=24) for a total of 9 weeks. The CMS protocol 
included the following individual stressors, used in varying order across weeks as previously 
described in detail [160]:  continuous overnight lighting; overnight water deprivation (18h) 
followed by 1 hour of empty water bottle replacement; 40-degree cage tilt; stroboscopic lighting 
(2-6 h; Chauvet mini-strobe CH-730; 8-12 flashes per second, 35 watts); overnight paired 
housing with another CMS-exposed rat (18h); damp bedding (300-500mL lukewarm water 
added to cage bedding); white noise (radio static, 85dB, 1-4 h, continuous or intermittent); and 
predator odor exposure (30-60 minutes exposure to a small vial of undiluted 2,4,5-
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trimethylthiazoline (TMT; Contech Intl.) opened in the housing room).  A typical week of 
stressors is diagrammed in Figure 14B.  
 
Sucrose Preference Test 
Anhedonia was measured using the sucrose preference test (SPT) as previously described in 
detail [160].  Rats were accustomed to the taste of sucrose by replacing ad libitum water with 1% 
sucrose for one week.  Tap water was returned to the cage for one day, and then rats were food- 
and water-deprived for 18 hours before the first baseline SPT was administered.   During the test, 
two graduated burets filled with either 1% sucrose solution or tap water were placed on the cage 
and rats were allowed to drink freely for one hour.  Total volume consumed of each fluid was 
recorded, and preference for sucrose was calculated as [(mL sucrose / total mL consumed) *100]. 
SPT was administered once per week to both CMS and Control groups (Figure 14). Body weight 
was measured weekly for the duration of the experiment.  
 
Radiotelemetry data collection and analysis 
Details of our cardiovascular data collection and analysis methods can be found in the previous 
chapter.  Blood pressure (BP) and heart rate (HR) were recorded as a 10-second average every 2 
minutes using Dataquest ART 4.0 software (Data Sciences International).  For HRV analysis, 
pulsatile BP was also recorded from groups of 8 rats at a time on different days of the same 
week, for 16-24 hours at a time. CMS was continued throughout the recordings.   
Time-domain HRV was calculated as the standard deviation of the inter-beat interval 
(IBI).  To evaluate autonomic contributions to HRV, frequency components of HRV were 
analyzed using the custom open source HRV analysis program, Physioscripts, which employs  a 
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band limited variance technique [34] (see Chapter 3).  Briefly, the event sequence of IBIs was 
resampled at 10 Hz, inspected for artifact, and a bandpass filter was applied before calculating 
the variance within the specified frequency range.  Boundaries for the frequency ranges were as 
follows [163]:  total power (TP) 0-5 Hz,  high frequency (HF) 1-3 Hz, low frequency (LF) 0.04-
1.0 Hz, and very low frequency (VLF) 0-0.39 Hz.   
 
Drug administration 
At the beginning of week 6, rats were implanted with osmotic minipumps (Alzet, 2ML4) 
containing one of the following:  candesartan (0.5mg/kg/day; Astra Zeneca), fluoxetine 
(4mg/kg/day; BioTrend), or 0.9% sterile saline (2mL). These doses were chosen based on 
previous reports that demonstrated their effects on behavior and neurobiology [66, 100, 101, 
171].  Minipumps were loaded and primed for several hours in 37ºC saline and were then 
surgically implanted subcutaneously in the interscapular region and wounds were closed with 
silk suture. A single dose of Ketoprofen (2mg/kg, s.c.) was administered as an analgesic.  Rats 
received 3-5 days of drug before the first post-drug SPT was administered (Figure 14A: CMS 
Week 6).  
 
Forced Swim Test 
The Forced Swim Test (FST) is a common test of antidepressant drug efficacy, with 
antidepressant drugs decreasing immobility in this test and increasing time spent in active 
behavior (i.e., swimming and climbing) [151, 172, 173].  This test was performed during CMS 
week 8.  During swim sessions, rats were placed in a clear Plexiglas cylinder  (20cm wide x 
61cm high) filled 45 cm high with 23-25ºC  tap water.  Two sessions were administered: a 15-
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minute session to acclimate the rats to the test and apparatus and a 5-minute testing session 24 
hours later, which was videotaped for behavioral scoring.  Based on the protocol in Cryan et al 
[151], three behaviors were scored: climbing, during which the rat’s front paws move in and out 
of the water; swimming, in which the rat’s front paws remain underwater, while the rat is mobile; 
and floating or immobility, in which the rat’s only movements are to keep its head above the 
water.  The 5-minute testing period was divided into sixty 5-second bins, and the predominant 
behavior during each bin was scored.  Scorers were kept blind to the experimental groups.   
 
Novelty-suppressed feeding test 
During Week 5 and Week 9 of CMS, anxiety-like behavior was assessed using the novelty-
suppressed feeding test (NSF).  Rats were food deprived for 24 hours before being placed in an 
open field (43cm x 43cm) with a food pellet in the center.  Latencies to approach and to consume 
the food pellet were recorded.  Once the rat bit the pellet, or a 15-minute time limit was reached, 
it was returned to its home cage, and latency to eat in the home cage was measured.  Testing took 
place between 10:00am and 1:00pm.   
 
Data Analysis 
Statistical analyses were performed using Microsoft Excel and PASW Statistics 18.0 (SPSS).  
Values are expressed as mean ± SEM.  One-way ANOVA was used for comparisons of CMS 
and Controls, and for comparisons of drug and treatment groups, a 2x3 ANOVA (Stress x Drug) 
was used, with Tukey HSD post-hoc tests where appropriate. Repeated measures ANOVA was 
used to identify significant differences across time, with least square difference (LSD) or Tukey 
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HSD test as appropriate. Pearson’s correlation was used to compare HRV and sucrose intake.  
For all tests, a two-tailed p-value of 0.05 or less was considered significant.   
4.4 RESULTS 
Sucrose Preference Test 
Weekly sucrose preference tests were used to assess anhedonic behavior (Figure 15A).  At 
baseline, before CMS began, there was no significant difference between groups (p=0.48).   By 
the end of the first week of CMS, the CMS-exposed rats reduced their preference for sucrose by 
approximately 30% (p=0.003), and this persisted through CMS week 5, consistent with our 
previous studies using bLR rats exposed to CMS [160].  In the beginning of week 6, rats were 
implanted with osmotic minipumps containing vehicle, candesartan or fluoxetine. When tested at 
the end of week 6, CMS-exposed rats receiving candesartan had significantly higher sucrose 
preference scores than those receiving vehicle (p=0.04) (Figure 15B), and sucrose preference in 
these rats was not different from either baseline or control rats.  The CMS group receiving 
fluoxetine was not significantly different from CMS-Veh rats during week 6, but was not 
significantly different from the CMS-candesartan group either, due to the marked variability in 
the fluoxetine-treated group (Figure 15B).   After four weeks of drug treatment (CMS week 9), 
CMS-Cand and CMS-Flx groups were not significantly different from unstressed Controls, 
though the untreated CMS-Veh group remained significantly anhedonic (p<0.001). No 
significant differences in SPT were observed among Control groups receiving vehicle, fluoxetine 
or candesartan at any time during the experiment.  Body weight, measured weekly throughout 
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the experiment, did not differ between groups at any time during the experiment (Figure 16); 
across the 9 weeks of the experiment rats typically gained approximately 55 grams. 
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Figure 15: Percent sucrose preference across 9 weeks of CMS 
15A:  Anhedonia was assessed weekly via SPT.  There were no significant differences in sucrose 
preference at baseline. CMS-exposed rats had significantly lower sucrose preference starting in CMS 
week 1 and continuing throughout the experiment. Values are means ± SEM. #: p<0.001, CMS vs. 
Control; *: p<0.01, CMS-Veh vs. CMS-Cand; ɸ: p<0.01, CMS-Veh vs. CMS-Flx. n=8 rats/group, except 
during week 5, as noted below.  
15B: Individual changes in sucrose preference in CMS-exposed rats from CMS week 5 to week 6. Group 
means are represented in black.  Candesartan rapidly increased sucrose preference scores, rats receiving 
fluoxetine had variable responses, and rats receiving saline did not have a significant change in sucrose 
preference. Note that one rat from the CMS-Flx group was excluded from this graph because it did not 
drink during week 5.  
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Figure 16: Increase in body weight across 9 weeks of CMS       
There were no significant differences among groups in increases in body weight or absolute body weights 
(not shown) during the experiment.  Baseline body weights are listed next to group names in the figure 
legend. Values are means ± SEM. n=8 rats/group. 
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Performance in the novelty-suppressed feeding test 
The NSF was used to assess anxiety-like behavior.  It was performed once in the fifth week of 
CMS (see Figure 14A) to confirm anxiety-like behavior before drugs began [64, 115, 116] and 
repeated during CMS week 9. At that time, both fluoxetine and candesartan significantly reduced 
latencies to approach (Figure 17A) and eat (Figure 17B) the food pellet (p<0.05). There were no 
significant differences among unstressed controls in either of these measures. Among all groups, 
there were no significant differences in either the number of times rats approached the pellet 
(Figure 17C) or latency to begin eating the in the home cage (Fig 17D).  These data indicate that 
candesartan and fluoxetine have similar anxiolytic effects in this model. 
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Figure 17: Results from novelty-suppressed feeding test (NSF) test during CMS week 9 
Anxiety-like behavior was assessed using the NSF test during the final week of CMS.  Candesartan and 
fluoxetine reduced latencies to approach (17A) and eat (17B) a food pellet placed in the center of an open 
field (p<0.05).  There were no significant differences in the number of times rats approached the food 
pellet (17C) or the latency to eat upon returning to the home cage (17D). Values are means ± SEM. *: 
p<0.05 vs. rats receiving vehicle; #:p<0.05 vs. control rats receiving the same drug. n=8 rats/group. 
 83 
Performance in the forced swim test 
The FST is frequently used as a predictive test of antidepressant drug efficacy. This test was 
performed during CMS week 8, after 3 weeks of drug treatment.  In unstressed Controls, 
candesartan significantly decreased time spent immobile (p=0.04) and increased swimming 
behavior (p=0.05, Figure 18A) but not climbing. Similarly, fluoxetine reduced immobility 
(p=0.02) and increased swimming (p=0.05) but not climbing. In the CMS-exposed group, there 
were no significant differences among treatment groups in immobility, swimming or climbing 
(Fig 18B), but all CMS groups showed decreased immobility and increased swimming compared 
to control rats treated with vehicle.  
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Figure 18: Results from the forced swim test (FST) during CMS week 8 
The FST was used to evaluate antidepressant actions of candesartan and fluoxetine. 18A: In control rats, 
immobility was decreased by candesartan (p=0.04) and fluoxetine (p=0.02) and swimming behavior was 
also increased by both drugs (p=0.05 for both).  18B: In CMS-exposed rats, there were no significant 
differences among treatment groups.  Values are means ± SEM. *: p<0.05 vs. rats receiving vehicle. Note 
that two rats from the Control-Flx group were excluded from analysis because they were large enough to 
balance on their tails during the FST testing period.  
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Resting blood pressure and heart rate 
HR and BP were chronically recorded throughout the experiment in 5 of the 8 rats in each group.  
At baseline, there were no significant differences in HR between groups.  For the first four weeks 
of CMS, CMS-exposed rats tended to have higher HR than Control rats, but this difference was 
not statistically significant (Figure 19B). There were also no significant differences in HR once 
drug administration began.  There were no significant differences in BP from baseline through 
Week 6 of CMS (Figure 19A).  During week 7 of CMS, one week after drug treatment had 
begun, CMS and Control rats receiving candesartan had significantly lower BP compared to rats 
from the CMS group receiving vehicle (p<0.005).  Hypotension persisted in these groups for the 
remainder of the experiment.  CMS-Flx rats also had reduced BP during CMS week 7 (p<0.01), 
but BP returned to pre-drug levels during weeks 8 and 9.  In addition to analysis of 24-hour 
averages, light-period and dark-period HR and BP were also analyzed separately, and no 
significant differences were detected.  
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Figure 19: Line graphs of 24-hour resting HR and BP across 9 weeks of CMS 
HR and BP were chronically recorded throughout the experiment. Values are means ± SEM. *: p<0.01 vs. 
rats receiving vehicle; #:p<0.01 vs. control rats receiving the same drug.  19A: Candesartan significantly 
decreased 24-hour resting BP in both CMS-exposed and control rats during CMS weeks 7-9 (p<0.005). 
Fluoxetine also decreased BP in CMS-exposed rats during CMS week 7 (p<0.01).  19B: There were no 
significant differences in 24-hour resting HR. n=8 rats/group. 
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Heart Rate Variability 
Time domain HRV was analyzed during the second quarter of the dark period (10p-1a) across all 
weeks of the experiment; this period was chosen because it was common to recordings in all rats 
during each week. During CMS weeks 1-4, there was a significant effect of CMS (p=0.01, 
Figure 20A). CMS reduced HRV during the first week (p<0.01), but was not significantly 
different from controls in weeks 2 and 3.  HRV was significantly reduced compared to controls 
during the fourth and fifth weeks of CMS (p<0.005, Figure 20B), and remained significantly 
reduced in CMS-Vehicle rats for the duration of the experiment.  HRV was significantly 
correlated with sucrose intake during week 5 (R=0.50, p=0.005, n=48), the final week of CMS 
before drugs were administered. HRV was also analyzed during the 3
rd
 quarter of the dark 
period, but as in the previous study (see Chapter 3) no differences were noted in this later period. 
Candesartan, fluoxetine, or vehicle were administered beginning CMS week 6, and there 
was a significant CMS x Drug interaction in HRV (p<0.05) during CMS weeks 7-9.  
Candesartan reversed the CMS-induced decrease in HRV by week 9 (p=0.03 vs. CMS-Veh, 
Figure 20B), and did not significantly change HRV in Control animals. Fluoxetine did not 
reverse the reduction in HRV in CMS, and during week 9, HRV in CMS-Flx rats was not 
significantly different CMS-Veh rats (Figure 20B).  Fluoxetine also significantly decreased 
HRV in the control group, starting in week 7 (p=0.05) and continuing throughout the experiment. 
As in the weeks before CMS began, HRV remained reduced in CMS-Veh rats compared to 
Control-Veh rats (p=0.003).    
 
 88 
Figure 20: Changes in time-domain HRV across 9 weeks of CMS, with and without drug treatment. 
HRV was measured during the second quarter of the dark period (11p-1a).  20A: Line graph of HRV 
across 9 weeks of CMS.  20B: Bar graph highlighting HRV during CMS week 5 (week before drug) and 
CMS week 9 (after 4 weeks of drug). Values are means ± SEM. *:p<0.01 vs. CMS-Veh; #:p<0.05 vs. 
Control-Veh; ɸ:p<0.05 vs. rats receiving fluoxetine of the same stress group. n=8 rats/group. 
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Frequency domain analysis of HRV 
To evaluate autonomic influences on HRV, frequency domain analysis was performed.  During 
week 5, the final week of CMS before drug treatment began, CMS-exposed rats had a significant 
decrease in total power (p=0.003), VLF power (p=0.004), and LF power (p=0.02) compared to 
control rats (data not shown).  Sucrose intake was significantly correlated with total power 
(R=0.48, p=0.008) and VLF power (R=0.48, p=0.009) during week 5.  By CMS week 9, total 
power, VLF, HF and LF were still reduced in CMS-Veh rats compared to Control-Veh rats 
(p<0.05) (Figure 21). Candesartan reversed this decrease in each of these frequency bands, and 
total power, VLF, HF, and LF in CMS-Cand rats were significantly higher than CMS-Veh rats 
(p<0.05).  Fluoxetine did not reverse CMS-induced decreases in total power, VLF and LF, and 
these values were not significantly different from the CMS-Veh group. Fluoxetine also reduced 
total power, VLF and LF in Control rats, compared to the Control-Veh group (p<0.05) and the 
Control-Cand group (p<0.05).  HF was not significantly different among Control groups.   
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Figure 21: Frequency domain components of HRV during CMS week 9 
To assess autonomic contributions to HRV, frequency domain components were also calculated during 
the second quarter of the dark period. 21A: Total Power (0-5Hz), 21B: high frequency power (HF, 1-
3Hz), 21C: low frequency power (LF, 0.04-1.0 Hz), 21D: very low frequency (VLF, 0-0.39 Hz).  Values 
are means ± SEM. *:p<0.01 vs. CMS-Veh; #:p<0.05 vs. Control-Veh; ɸ:p<0.05 vs. rats receiving 
fluoxetine of the same stress group.  n=8 rats/group. 
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4.5 DISCUSSION 
Cardiovascular disease and depression are highly comorbid. Though the mechanism that 
connects them is not known, some common physiological, hormonal, and neurotransmitter 
systems are disrupted in both disorders. One such system is the RAS, which is well-known for its 
effects on cardiovascular function and may also be involved in altered mood states such as 
anxiety and depression [100, 101, 108, 171, 174].  The major finding of this study is that 
candesartan, an ARB used clinically in patients with hypertension or cardiac disease, reverses 
both the behavioral and the cardiovascular alterations induced by the CMS model of depression.  
Additionally, the effects of candesartan in our model occur faster and more completely than the 
SSRI fluoxetine.  
 
CMS induces depression-like effects 
bLR rats, which are especially vulnerable to the anhedonic effects of CMS [160], were exposed 
to 5 weeks of CMS before drug treatment began.  CMS induced anhedonia, as measured by 
preference for a dilute sucrose solution, increased anxiety-like behavior in the NSF test, and 
reduced HRV and its frequency components.  These data replicate previous findings from our lab 
[160] and others [49-53, 68] regarding the effects of CMS on behavior and cardiovascular 
function.  
 
Candesartan reverses the behavioral effects of CMS 
Drug treatment was started in the beginning of CMS week 6, and rats were tested for anhedonic 
behavior at the end of the week, 3-5 days after the start of drug administration.  In this span of 
time, candesartan fully reversed anhedonia.  Each rat in the CMS-Cand group drank 100% 
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sucrose within days of receiving candesartan, and this group was not significantly different from 
control groups on this measure for the remainder of the experiment.   Thus, candesartan has 
robust antidepressant properties in this model. Previous clinical data indicate that patients taking 
ACE inhibitors have improved mood [104] and those taking ARBs are less likely to be taking 
antidepressants [106].  This study provides further experimental evidence of the mood-altering 
properties of ARBs as well as an appropriate model in which to study them.  
AT1Rs are located at every level of the HPA axis [98], and blockade with a centrally-
acting ARB like candesartan attenuates the HPA response to acute stress [100].  Chronic 
pretreatment of candesartan greatly reduces anxiety-like behavior in the elevated plus maze in 
rats, possibly via HPA axis blockade or prevention of the sympathoadrenal response [101].  In 
the current study, candesartan also had anxiolytic effects in the NSF test. The NSF test has been 
used frequently in models of depression because chronic, but not acute, antidepressant 
administration reduces behavioral latencies, providing excellent predictive validity for the time 
course of antidepressants ([64, 115, 116]).  In CMS-exposed rats, candesartan attenuated the 
latency to approach and to begin to eat the food pellet. Latencies to eat upon return to the home 
cage were not different among groups, indicating that reduced latencies in the open field are not 
due to differences in hunger or appetitive value of the food pellet.   These results corroborate 
previous reports of the anxiolytic properties of candesartan in a test with relevance for the effects 
of antidepressant drugs.  
 
Candesartan reverses CMS-induced reduction in HRV  
bLR rats’ vulnerability to CMS-induced anhedonia is associated with a decrease in HRV, 
indicating an imbalance in sympathovagal control of the heart (Chapter 3).  Reduced HRV is a 
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significant marker of risk for cardiac mortality that has been observed in both depression and 
cardiovascular disease patients [19, 31, 37, 40]. Candesartan reversed the CMS-induced decrease 
in HRV, restoring it to control (i.e. unstressed) levels. As mentioned in Chapter 3, frequency 
domain analysis of HRV is a technique that indirectly measures autonomic contributions to 
HRV. Total power across the frequency spectrum is related to overall autonomic balance,  HF 
power is used as an index of parasympathetic influence on HRV, and LF power appears to be 
influenced by both sympathetic and parasympathetic elements [22, 35]. Especially pertinent to 
this study, VLF power may reflect cardiovascular modulation by the renin-angiotensin system 
[29, 35, 36] or its effects on parasympathetic influence on the heart.  In human patients, VLF is 
considered one of the most reliable indices of risk for cardiac mortality [24], and accounts for 
nearly 30% of the depression-related risk for heart attack and death [31].  CMS significantly 
reduced these frequency components compared to unstressed controls, and this reduction was 
completely reversed by candesartan.  Thus, in addition to improving anhedonic behavior within 
days, candesartan restores sympathovagal balance, measured by HRV and its frequency 
components.   
 
Fluoxetine reverses the behavioral, but not the cardiovascular effects of CMS  
Fluoxetine also reversed CMS-induced anhedonia, though more slowly than candesartan. 
Individual responses to the initial week of fluoxetine treatment varied, which may parallel the 
varied responses of depressed patients to the initiation of SSRI treatment [175].  Nonresponse to 
initial antidepressant treatment is an especially serious issue.  Approximately 30% of depression 
patients do not show improvement after the first course of antidepressant pharmacotherapy 
[176], and reports suggest that response rates decrease with each subsequent course of treatment 
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[177].  The weeks-long delay in reversal of anhedonia with SSRIs, also observed in our animal 
model, is a clinically significant problem; this delay in complete therapeutic efficacy may 
contribute to patient non-adherence and discontinuation of antidepressant therapy.  Therefore, a 
drug that quickly and robustly improves anhedonia, one of the core signs of depression [12], 
would be highly beneficial to patient outcomes.  Additionally, fluoxetine, like candesartan, 
reduced anxiety-like behavior in the NSF, as demonstrated in previous reports [64, 115, 116], 
although this was tested only after 4 weeks of drug treatment so differences in time course for 
the development of this action were not assessed. The more rapid time course of candesartan 
versus fluoxetine in reversing CMS-induced anhedonia suggests that these two drugs may be 
exerting their antidepressant effects via very different mechanisms.   
Currently, there is no consensus in the clinical literature as to whether SSRIs reduce the 
cardiac mortality risk associated with depression, even as they relieve signs of depression [88, 
90]. Various studies have shown that SSRIs either improve [19, 87], have no effect on [88], or 
worsen [89] cardiovascular disease and mortality.  A study using the CMS model of depression 
demonstrated that fluoxetine prevented anhedonia, but not reductions in HRV [53].  We found 
that fluoxetine did not reverse the CMS-induced decrease in HRV.  Though fluoxetine increased 
HRV slightly in CMS-exposed rats, this increase was not statistically significant from untreated 
CMS-exposed rats.   Fluoxetine also did not improve decreases in the frequency components of 
HRV.  Thus, despite its improvement of the anhedonic and anxiety-like behavior of CMS, we 
found that fluoxetine does not change the potentially detrimental cardiovascular effects 
associated with CMS, at least during the time course of this experiment.   
Interestingly, fluoxetine administration decreased HRV in control rats to the same degree 
as CMS exposure.  This suggests that fluoxetine may have detrimental cardiovascular effects 
 95 
independent of its effect on mood, possibly due to interference with normal serotonergic 
influence of cardiovascular function [178].   Indeed, as mentioned previously, SSRIs can produce 
cardiovascular disturbance such as arrhythmia in healthy patients without cardiovascular disease  
[84]. Findings such as these may become increasingly relevant as SSRIs are prescribed for a 
variety of conditions not directly related to mood [179-181].  
 
Candesartan has antidepressant effects in the forced swim test  
The FST is often referred to as a test of learned helplessness [151, 172, 173], operationally 
defined as an increase in immobility and a decrease in swimming and climbing behaviors.  No 
differences were observed among CMS-exposed rats receiving vehicle or drugs. This is likely an 
indication of the limited utility of the FST, rather than the effects of CMS on FST behavior.  The 
FST was initially developed to test antidepressant drug efficacy, and not depression-like 
behavior, per se [172, 182]. When examined in the context of other robust measures of 
depression-related behaviors, especially the core symptom of anhedonia, these results and past 
reports suggest that the FST is most reliably employed as an acute test to predict antidepressant 
drug effects [182, 183].  
 In Control rats not exposed to CMS, candesartan reduced immobility and increased 
swimming behavior to the same degree as fluoxetine.  Past reports have suggested that 
antagonists of the serotonergic system increase swimming behavior in the FST, while 
catecholaminergic antagonists increase climbing behavior [151, 173]. Thus our data suggest that 
one possible mechanism by which candesartan might be exerting this change is via an interaction 
with  the central serotonergic system [184].  Similar antidepressant effects of drugs that inhibit 
the RAS have been reported in acute tests of antidepressant efficacy. For instance, the AT1R 
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antagonist losartan and the ACE inhibitor captopril both give positive anti-depressant like effects 
in the FST in mice [107, 108].  Previous data from our lab confirm that chronic candesartan also 
reduces immobility and increases swimming in supplier-bred Sprague Dawley rats [185].   
 
Rapid effects of candesartan suggest a novel antidepressant mechanism 
The positive effect of candesartan and fluoxetine in the FST, specifically the increase in 
swimming behavior, suggests that the two drugs may exert their effects via a similar mechanism. 
Indeed, there is evidence that the RAS does interact with the serotonergic system [186]. 
However, the rapid reversal of anhedonia by candesartan suggests that it may be working via a 
different mechanism.  One of the major clinical concerns regarding SSRI treatment is the delay 
in onset that most patients experience.  Though SSRIs such as fluoxetine acutely increase 
synaptic levels of serotonin, downstream effects such as increases in brain derived neurotrophic 
factor (BDNF) or increases in hippocampal neurogenesis may be necessary for full 
antidepressant efficacy [64, 187, 188]. This paradox remains a controversial issue, and the 
question of the acute versus the long-term mechanisms of SSRI efficacy remains largely 
unanswered.  
Despite candesartan’s rapid reversal of anhedonia, HRV is not improved until three 
weeks later. This suggests that though they are highly comorbid, depression and cardiovascular 
dysfunction are dissociable. Indeed, in addition to reports of antidepressant effects on HRV, 
there is evidence that cognitive behavioral therapy improves signs of depression but does not 
alter cardiac mortality [90].  Therefore, improving the psychological aspects of depression—
whether by antidepressant treatment or by psychotherapy—does not necessarily reduce 
cardiovascular risk.   
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In addition to interactions with the serotonergic system, there are a number of 
mechanisms, both direct and indirect, by which candesartan may be reversing anhedonia and 
reduced HRV.  For instance, chronic peripheral administration of candesartan reduces the 
sympathoadrenal response to stress [189].  The dose and administration of candesartan used in 
the current study have been shown to have central effects as well [190], and may also be exerting 
direct effects on central AT1Rs in the hypothalamus or brainstem to alter both cardiovascular 
and behavioral changes of CMS.  Indeed, AT1Rs are co-localized with corticotrophin-releasing 
hormone (CRH) positive neurons in the PVN [99], and two weeks of pretreatment with 
candesartan reduces the HPA response to isolation stress [100, 189].  Candesartan also has 
demonstrated anti-inflammatory effects [191], decreasing, for example, cold-restraint stress-
induced increase in gastric ulcers in rats [102], and peripheral and central release of cytokines in 
response to an endotoxin [192, 193]. Plasma levels of pro-inflammatory cytokines, especially 
interleukin-6 (IL-6),  IL-1β, and tumor necrosis factor-a (TNF-a) are increased in depression and 
are thought to contribute to some of the somatic symptoms of depression, such as fatigue and 
reduced appetite [18].  Furthermore, there is evidence that inflammatory markers such as 
cytokines are correlated with decreased HRV [42, 194, 195], and cytokine levels are increased in 
chronic heart failure in humans [196].  Indeed, we found that CMS increased plasma levels of 
IL-1β four-fold in plasma samples collected at the termination of the current experiment, and 
candesartan attenuated this large increase to control levels (Stedenfeld, Sved & Saavedra, 
unpublished observations), as did fluoxetine.  
Given the distinct latencies of the reversal of behavioral and cardiovascular effects of 
CMS, candesartan may be affecting these changes via one or more of the above mechanisms.  Of 
course, isolating the precise mechanism is additionally complex because each of the systems 
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mentioned above—the sympathoadrenal system, the HPA axis, and pro-inflammatory 
cytokines—also influences the others.   
 
Candesartan is a novel, effective treatment for comorbid depression and cardiovascular 
disease 
Currently, candesartan is frequently prescribed for hypertension and heart failure, is tolerated 
well with few negative side effects, and has been shown to reduce cardiac mortality [197]. This 
study presents evidence that candesartan has profound antidepressant effects, including rapid 
reversal of anhedonia, and attenuated anxiety-like behavior.  Furthermore, candesartan reverses 
the reduced HRV associated with anhedonia, thereby markedly decreasing risk for cardiac 
mortality.  These findings suggest that candesartan and other ARBs may be novel therapies for 
the treatment of comorbid depression and cardiovascular disease, and may be more effective than 
traditionally-prescribed antidepressant treatments such as SSRIs. 
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5.0  GENERAL DISCUSSION 
5.1 SUMMARY AND INTERPRETATIONS OF CURRENT FINDINGS 
Epidemiological and clinical studies using human patients have provided convincing evidence 
that depression and cardiovascular disease are highly comorbid [1, 6, 10, 20, 31, 37, 40, 41, 44] 
and that depression is an independent risk factor for cardiac mortality  [2-4, 31], both in patients 
with existing  cardiovascular disease [38, 43]   and  in medically well individuals [1].  
Experimental animal models have been useful in further elucidating mechanisms that may be 
common to both disorders [49-52, 162].  The studies presented in this dissertation used the CMS 
model of depression, a well-validated animal model that uses intermittent unpredictable mild 
stressors to induce anhedonia, one of the core diagnostic criteria for depression [12, 46, 47, 49-
52, 68, 198].  CMS also induces a constellation of behavioral, physiological, and neuroendocrine 
responses that closely resemble those observed in depressed patients [47], including  a decrease 
in HRV, a sign of altered autonomic control of the heart and a marker of cardiac mortality risk 
[49, 53, 68].  CMS-induced anhedonia is reversed by antidepressant treatment [53, 60, 61], 
however there is evidence that pretreatment with an SSRI does not improve an anhedonia-
associated decrease in HRV, even when depression is improved [53].   This phenomenon has 
been reported in human patients as well [88, 89], suggesting that in some individuals the cardiac 
mortality risk associated with depression may persist even when depression is treated.   
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 Many hormonal and neurohumoral systems are activated in both depression and heart 
disease.  One of these systems is the RAS, which has an established role in cardiovascular 
regulation [91, 92]. Additionally, antagonists of the RAS such as the ARB candesartan greatly 
reduce the behavioral, neuroendocrine, and sympathoadrenal effects of stress [98, 100, 101, 174, 
189], and there is some evidence that ARBs may have antidepressant properties as well [104, 
106, 108].  Therefore, the ultimate goal of these experiments was to test the hypothesis that 
candesartan reverses both the anhedonic and cardiovascular changes induced by CMS, and to 
compare these results with those of the SSRI fluoxetine.  
Preliminary CMS experiments in our lab showed that supplier-bred Sprague Dawley rats 
had variable responses to four weeks of CMS, and final sucrose preference was positively 
correlated with pre-CMS locomotor response to an open field (Stedenfeld & Sved, unpublished 
observation).  Indeed, one approach to developing models of genetic predisposition to mood 
disorders is to selectively-breed animals from within two opposite ends of a behavioral spectrum.   
We took advantage of one such model, in which rats were selectively-bred based on locomotor 
response to novelty, bHR and bLR rats (described in detail in Chapter 2).  Previously reported 
differences in mood-related behavior in bHR versus bLR rats [71, 81], led us to hypothesize that 
the bHR/ bLR distinction might also predict behavioral responses to CMS-exposure.  We present 
these results in Chapter 2, providing evidence that bLR rats are especially vulnerable to the 
anhedonic effects of CMS and also have increased anxiety-like behavior compared to bHR rats.  
Therefore, the bHR/bLR model appears to be ideal for studying the interactions between 
inherited vulnerability and environmental stress that may result in depression.  At present, little is 
known about the underlying neurobiology that might contribute to this difference between 
bHR/bLR rats, and more research in this area is necessary.   
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 We expanded upon these behavioral findings in Chapter 3 to demonstrate that the 
respective vulnerability and resistance of bLR and bHR rats to anhedonia is bLR rats  had large 
decreases in HRV and its frequency components, increased resting HR, and increased 
cardiovascular reactivity to an acute stressor.  associated with CMS-induced changes in 
cardiovascular function that mirror those in depressed patients.  These results parallel reports that 
depressed patients display large decreases in HRV [31] [19], and severity of depression is 
correlated with reduced HRV [21, 33].  Therefore, the bHR/bLR model is a additionally useful 
for the study of comorbid depression and cardiovascular disturbances.  
It is likely that multiple genes are working together to produce vulnerability to mood disorders 
such as depression [70]. Models such as the bHR/bLR model take advantage of inborn trait 
variability to integrate knowledge of behavioral endophenotypes and the genetic and molecular 
basis of that behavior.  As we learn more about how the prenatal environment and early life 
experience shape the development of neural circuits [150, 199], these types of models will 
become ever more useful. 
Having established a robust model of vulnerability to CMS-induced anhedonia and 
cardiovascular alterations, in Chapter 4 we tested the effectiveness of candesartan, an ARB 
found to reduce cardiovascular mortality in human patients [197], in reversing CMS-induced 
anhedonia and reduced HRV.  Candesartan reversed anhedonia within the first week of 
treatment, and improved reduced HRV by the fourth week of treatment.  It also reduced anxiety-
like behavior in CMS-exposed rats and improved scores on the FST in control rats.  By contrast, 
fluoxetine also improved anhedonia, but only after 4 weeks of treatment. Fluoxetine did not 
improve HRV or its frequency components and, in fact, these measures were decreased in 
control rats receiving fluoxetine.  Thus, candesartan has both robust antidepressant effects and 
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improves CMS-induced changes in autonomic control of cardiovascular function, and may be 
more effective than fluoxetine in the treatment of comorbid depression and cardiovascular 
disease.  
 Notably, only one dose of each drug was administered in this experiment, via 
subcutaneous minipump.  The dose of candesartan (0.5mg/kg/day, s.c.) was chosen based on 
reports that this dose and route of administration has effects on central AT1Rs in areas such as 
the PVN [98, 100, 101, 189, 190]. It is not clear whether peripherally-administered candesartan 
is accessing the brain by crossing the blood-brain barrier directly or by accessing AT1Rs in 
circumventricular organs [98].  This dose of candesartan caused a significant hypotension in both 
CMS-exposed and control rats. However, in control rats, other measures of cardiovascular 
function, such as 24-hour resting HR, HRV, and frequency components of HRV were not 
affected by candesartan, suggesting that candesartan is not causing significant changes in overall 
sympathetic or parasympathetic control of cardiovascular function.   Additionally, rats receiving 
candesartan did not have any noticeable behavioral differences from rats receiving fluoxetine in 
tests that required physical exertion, such as the FST.  
The dose of fluoxetine (4mg/kg/day, s.c.) was chosen based on reports that it attenuated 
chronic stress-induced CRH expression in the PVN [66].  Using this chronic dose of fluoxetine, 
we observed a delay in onset of full antidepressant actions that parallels the one seen in 
depression patients.   There were no changes HRV within 4 weeks of fluoxetine treatment, 
though it is possible that this change may have become apparent with a longer treatment period.  
For instance, four weeks of pretreatment with fluoxetine (10mg/kg/day, i.p.) partially prevented a 
CMS-induced decrease in HRV in Sprague Dawley rats [53].  
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5.2 POSSIBLE MECHANISMS BY WHICH CANDESARTAN REVERSES 
DEPRESSION-LIKE BEHAVIOR AND CARDIOVASCULAR DYSFUNCTION 
Candesartan had temporally distinct effects on behavioral and cardiovascular outcomes. This 
suggests that though depression and cardiovascular disease have a comorbid, bidirectional 
relationship, they are dissociable, and can be resolved individually.  Thus it is likely that the 
effects of candesartan are mediated via interactions with one or more of the following 
physiological systems, all of which play a role in both depression and cardiovascular disease 
[108, 200].  
 
Inhibition of HPA axis activity  
Clinical studies have linked extended hyperactivity of the HPA axis not only with anxiety 
disorders but also depression [14, 15, 109, 201] . Depressed patients have an increase in HPA 
activity marked by increased levels of CRH in the cerebrospinal fluid and increased plasma 
cortisol [17, 202].  In rats, AT1Rs have been found at each level of the HPA axis [98].  They are 
heavily co-localized with CRH-positive neurons in the parvocellular region of the PVN, and 
appear to directly modulate their activity [99]. Angiotension stimulation increases CRH synthesis 
[99] and two weeks of pretreatment with candesartan reduces the HPA response to isolation 
stress [100, 189].  AT1Rs are also located in the median eminence, the site where CRH is 
released into the portal circulation, the pituitary, where ACTH is released to the bloodstream, 
and the adrenal glands, which release corticosterone into the circulation [98].   
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Although previous studies have found a modest increase in plasma corticosterone 
following 4 weeks of CMS [51], preliminary results from the current studies do not strongly 
suggest a central role of altered HPA activity. Indeed, terminal plasma corticosterone levels were 
not significantly higher in CMS-exposed versus control rats (from Chapter 4), nor were there 
significant drug effects across groups (Stedenfeld, Sved & Saavedra, unpublished observation). 
However, CMS is not typically used for longer than 4-6 weeks, and therefore little is known 
about adaptations that might take place in longer applications.  Furthermore, it is possible that 
acute stress-evoked levels of corticosterone, which were not measured, may be different among 
groups.   
 
Inhibition of sympathoadrenal responses to CMS 
There are significant interactions between the HPA axis and the sympathoadrenal response to 
stress and depression [203], and sympathoadrenal activity is increased in depression patients and 
in patients with cardiovascular disease, as marked by increase norepinephrine excretion levels 
[13].  In rats, AT1Rs are expressed in the adrenal cortex [204], and chronic peripheral 
administration of candesartan prevents the cold-restraint stress-induced increase in adrenal 
content of tyrosine hydroxylase mRNA, epinephrine and norepinephrine [91, 189].  
Sympathoadrenal activity is also regulated by pre-sympathetic brainstem areas such as the rostral 
ventrolateral medulla, which is rich in AT1Rs [205, 206]. 
 
Effects on hippocampal neurogenesis  
There is evidence that antidepressants stimulate adult hippocampal neurogenesis [187, 188] , and 
that hippocampal neurogenesis may be required for the full therapeutic effects of antidepressants 
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[64]. Indeed, the latency of therapeutic actions of antidepressants is consistent with the time 
course of integration of newly adult-born hippocampal neurons [207, 208].  However, though 
there is some evidence that angiotensin II may have apoptotic effects [209], ARBs do not appear 
to increase neurogenesis [210-212].  Data from our lab demonstrating that chronic candesartan 
does not increase the number of  hippocampal progenitor cells labeled with 5-bromo-2'-
deoxyuridine (BrdU) [185]  support this observation.  
 
Anti-inflammatory effects and attenuation of circulating cytokines 
Pro-inflammatory cytokines such as TNF-a, IL-6, and IL-1B are increased in depression [18].   
Furthermore, cytokine levels are increased in chronic heart failure and following myocardial 
infarction in humans [196, 213], and there is evidence that inflammatory markers such as 
cytokines are correlated with decreased HRV [42, 194, 195].  In addition to its direct antagonism 
of AT1Rs, candesartan has demonstrated anti-inflammatory effects.  Candesartan decreases the 
immune response to an endotoxin [192, 193],  is neuroprotective [191, 214],  and decreases 
stress-induced gastric ulcerations [102, 103].  As mentioned in the discussion section of Chapter 
4, we found that CMS increased plasma levels of IL-1β four-fold, and candesartan attenuated this 
large increase to control levels (Stedenfeld, Sved & Saavedra, unpublished observation).  
Therefore, it is possible that candesartan is having positive effects on anhedonia and 
cardiovascular function via an anti-inflammatory mechanism.  The rapid reversal of anhedonia 
would support this idea, as a single dose of etanercept, a TNF-a antagonist, was able to decrease 
chronic heart failure-induced anhedonia to control levels in rats [55].   
 Antagonists of the RAS also have positive effects on cerebrovascular inflammation, and 
ARBs such as candesartan have been shown to reduce mortality after ischemic stroke [215], 
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possibly by increasing cerebral blood flow [216]. These effects have been shown to be 
independent of effects on AT1Rs, and may instead involve decreasing oxidative stress [217] or 
restoring endothelial function [191, 218].   There is also evidence that global and regional 
cerebral blood flow is altered in depression, and antidepressant therapies restore proper blood 
flow [219, 220]; it has been suggested that increases in cerebral blood flow could act as a 
biomarker of antidepressant drug effects [221].  It is possible, then, that candesartan is reversing 
anhedonia via anti-inflammatory effects on the cerebral vasculature that increase cerebral blood 
flow.   
5.3 FUTURE DIRECTIONS 
Findings presented in this dissertation provide evidence of a model of increased vulnerability to 
CMS-induced depression-like behavior and comorbid cardiovascular dysfunction, marked by 
reduced HRV and frequency domain components of HRV.  The bHR/bLR rat model offers an 
excellent way of studying the genetic and environmental interactions that result in depression-
like behavior.  However, as previously mentioned, the neurobiological mechanisms that 
differentiate the bHR and bLR rats are not well-known.  Though some information is available 
from supplier-bred rats that were classified as high- or low-responder rats (e.g. LR rats have 
increased hippocampal glucocorticoid receptors [76]), not all of these measures have been 
replicated in bHR/bLR rats.  Indeed, these analyses are planned for tissues collected from the 
current studies.  
Furthermore, there is evidence that not all characteristics of the supplier-bred HR/LR 
classified rats parallel those in selectively-bred bHR/bLR rats.  For instance,  it has been reported 
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that when exposed to a repeated social defeat stress, rats classified as HR had greater anxiety-like 
behavior and reduced sucrose preference compared to unstressed controls [222].  However, there 
were only very small differences, if any, between HR and LR rats on these measures, further 
demonstrating that the bHR/bLR model is truly unique in the marked difference in behavior and 
autonomic cardiovascular function between the two rat strains.  Yet this raises the question of 
how the bHR/bLR rat strains relate to typical Sprague Dawley rats.  Do bHR/bLR rats still 
represent extreme ends of a continuum of normal Sprague Dawley rat behavior, or do they now 
represent an entirely new rat strain? Exposing supplier-bred HR/LR rats to four weeks of CMS 
(e.g. replicating Chapters 2 and 3) would be one way to address many of these questions.  
 This dissertation also presents evidence that the ARB candesartan reverses both 
anhedonia and changes in cardiovascular function in bLR rats that are vulnerable to these CMS-
induced changes.  The question of exactly how candesartan is effecting these changes was 
addressed at length in the previous section and remains an important area of research.  Some of 
these mechanisms will be investigated in future analyses of brains and plasma collected from this 
experiment.  These candidate mechanistic systems are located both centrally and in the 
periphery, and it is likely that the subcutaneous dose of candesartan we used has effects in both.  
Answering the question of where candesartan’s actions are necessary for its antidepressant 
effects—in the brain or in the periphery—perhaps by infusing candesartan directly into the 
ventricles rather than subcutaneously, would be a further step toward understanding the 
mechanism by which candesartan is working.  Finally, if it is determined that candesartan is 
working via an indirect mechanism, such as by anti-inflammatory actions, it is possible that that 
system could be a specific target for further antidepressant drug discovery.  
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5.4 RELEVANCE AND CONCLUSIONS 
Cardiovascular disease and major depression are currently two of the most detrimental disorders 
in developed countries [8, 9].  The comorbid relationship between depression and cardiovascular 
disease has received attention in recent years as being a serious health concern warranting 
increased education and awareness in the clinical and health-provider communities [10].  
Depression is an independent risk factor for coronary heart disease both in patients with 
cardiovascular disease as well as medically healthy individuals [1, 38, 39, 44, 170] and is a 
significant independent predictor of mortality within 18 months following a heart attack [2, 4].  It 
is alarming, then, that many reports conclude that antidepressant drugs might not improve 
cardiac mortality, even when they improve depression [19, 53, 84, 90, 223].  Because current 
antidepressant drugs have a delay in reaching full effect and have varying success rates and 
tolerability [176, 224], increased research efforts are necessary in antidepressant drug discovery. 
Furthermore, those efforts should focus on drugs that also address physiological changes that 
accompany depression.  Progress is already being made in this area, as drugs that regulate 
peptides such as  CRH [16],  oxytocin [225], vasopressin [226], melatonin [227], and, indeed, the 
RAS [108] are gaining attention [228].   
Furthermore, research into the physiological corollaries of mental disorders has 
implications beyond finding appropriate pharmacological treatment.  Hopefully, as depression is 
increasingly recognized as a disorder with serious physiological repercussions and not merely a 
mental disorder, the stigma of such disorders will be further eradicated. There is growing 
evidence, for example, of improved outreach and treatment for depression and anxiety disorders 
in vulnerable populations such as postpartum mothers [229, 230] and veterans returning from 
combat [231, 232].   The experiments described in this dissertation, and future experiments that 
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examine the relationship between depression and cardiovascular disease, will increase our 
understanding of the possible mechanisms connecting these two disorders and will encourage 
more effective treatments in order to improve patients’ quality of life.   
 
 
 
 
 
 
 
 
 
 
 110 
BIBLIOGRAPHY 
[1] Penninx, B. W., Beekman, A. T., Honig, A., Deeg, D. J., Schoevers, R. A., van Eijk, J. T., et 
al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch 
Gen Psychiatry. 2001,58:221-7. 
[2] Frasure-Smith, N., Lesperance, F., Talajic, M. Depression following myocardial infarction. 
Impact on 6-month survival. JAMA. 1993,270:1819-25. 
[3] Carney, R. M., Blumenthal, J. A., Catellier, D., Freedland, K. E., Berkman, L. F., Watkins, L. 
L., et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol. 
2003,92:1277-81. 
[4] Frasure-Smith, N., Lesperance, F., Talajic, M. Depression and 18-month prognosis after 
myocardial infarction. Circulation. 1995,91:999-1005. 
[5] Schleifer, S. J., Macari-Hinson, M. M., Coyle, D. A., Slater, W. R., Kahn, M., Gorlin, R., et 
al. The nature and course of depression following myocardial infarction. Arch Intern Med. 
1989,149:1785-9. 
[6] Lesperance, F., Frasure-Smith, N., Talajic, M. Major depression before and after myocardial 
infarction: its nature and consequences. Psychosom Med. 1996,58:99-110. 
[7] Glassman, A. H., Shapiro, P. A. Depression and the course of coronary artery disease. Am J 
Psychiatry. 1998,155:4-11. 
[8] Murray, C. J., Lopez, A. D. Evidence-based health policy--lessons from the Global Burden of 
Disease Study. Science. 1996,274:740-3. 
[9] Mathers, C. D., Loncar, D. Projections of global mortality and burden of disease from 2002 
to 2030. PLoS Med. 2006,3:e442. 
[10] Lichtman, J. H., Bigger, J. T., Jr., Blumenthal, J. A., Frasure-Smith, N., Kaufmann, P. G., 
Lesperance, F., et al. Depression and coronary heart disease: recommendations for screening, 
referral, and treatment: a science advisory from the American Heart Association Prevent ion 
Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council 
on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and 
Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 
2008,118:1768-75. 
[11] Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., Monteggia, L. M. 
Neurobiology of depression. Neuron. 2002,34:13-25. 
[12] Association, A. P. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. 
Washingtion, DC: American Psychiatric Association; 1994. 
[13] Otte, C., Neylan, T. C., Pipkin, S. S., Browner, W. S., Whooley, M. A. Depressive 
symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: 
findings from the Heart and Soul Study. Am J Psychiatry. 2005,162:2139-45. 
 111 
[14] Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) 
antagonists to treat depression and anxiety. J Psychiatr Res. 1999,33:181-214. 
[15] Holsboer, F. The corticosteroid receptor hypothesis of depression. 
Neuropsychopharmacology. 2000,23:477-501. 
[16] Holsboer, F., Ising, M. Central CRH system in depression and anxiety--evidence from 
clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008,583:350-7. 
[17] Nemeroff, C. B., Widerlov, E., Bissette, G., Walleus, H., Karlsson, I., Eklund, K., et al. 
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in 
depressed patients. Science. 1984,226:1342-4. 
[18] Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., Kelley, K. W. From 
inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev 
Neurosci. 2008,9:46-56. 
[19] Carney, R. M., Freedland, K. E., Stein, P. K., Skala, J. A., Hoffman, P., Jaffe, A. S. Change 
in heart rate and heart rate variability during treatment for depression in patients with coronary 
heart disease. Psychosom Med. 2000,62:639-47. 
[20] Carney, R. M., Freedland, K. E., Stein, P. K. Anxiety, depression, and heart rate variability. 
Psychosom Med. 2000,62:84-7. 
[21] Krittayaphong, R., Cascio, W. E., Light, K. C., Sheffield, D., Golden, R. N., Finkel, J. B., et 
al. Heart rate variability in patients with coronary artery disease: differences in patients with 
higher and lower depression scores. Psychosom Med. 1997,59:231-5. 
[22] Heart rate variability. Standards of measurement, physiological interpretation, and clinical 
use. Task Force of the European Society of Cardiology and the North American Society of 
Pacing and Electrophysiology. Eur Heart J. 1996,17:354-81. 
[23] Kleiger, R. E., Miller, J. P., Bigger, J. T., Jr., Moss, A. J. Decreased heart rate variability 
and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 
1987,59:256-62. 
[24] Bigger, J. T., Jr., Fleiss, J. L., Steinman, R. C., Rolnitzky, L. M., Kleiger, R. E., Rottman, J. 
N. Frequency domain measures of heart period variability and mortality after myocardial 
infarction. Circulation. 1992,85:164-71. 
[25] Glassman, A. H. Depression, cardiac death, and the central nervous system. 
Neuropsychobiology. 1998,37:80-3. 
[26] Grippo, A. J., Johnson, A. K. Stress, depression and cardiovascular dysregulation: a review 
of neurobiological mechanisms and the integration of research from preclinical disease models. 
Stress. 2009,12:1-21. 
[27] Gehi, A., Mangano, D., Pipkin, S., Browner, W. S., Whooley, M. A. Depression and heart 
rate variability in patients with stable coronary heart disease: findings from the Heart and Soul 
Study. Arch Gen Psychiatry. 2005,62:661-6. 
[28] Kop, W. J., Synowski, S. J., Gottlieb, S. S. Depression in heart failure: biobehavioral 
mechanisms. Heart Fail Clin. 2011,7:23-38. 
[29] Bonaduce, D., Marciano, F., Petretta, M., Migaux, M. L., Morgano, G., Bianchi, V., et al. 
Effects of converting enzyme inhibition on heart period variability in patients with acute 
myocardial infarction. Circulation. 1994,90:108-13. 
[30] Curtis, B. M., O'Keefe, J. H., Jr. Autonomic tone as a cardiovascular risk factor: the dangers 
of chronic fight or flight. Mayo Clin Proc. 2002,77:45-54. 
 112 
[31] Carney, R. M., Blumenthal, J. A., Freedland, K. E., Stein, P. K., Howells, W. B., Berkman, 
L. F., et al. Low heart rate variability and the effect of depression on post-myocardial infarction 
mortality. Arch Intern Med. 2005,165:1486-91. 
[32] Huikuri, H. V., Jokinen, V., Syvanne, M., Nieminen, M. S., Airaksinen, K. E., Ikaheimo, M. 
J., et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb 
Vasc Biol. 1999,19:1979-85. 
[33] Stein, P. K., Domitrovich, P. P., Kleiger, R. E., Schechtman, K. B., Rottman, J. N. Clinical 
and demographic determinants of heart rate variability in patients post myocardial infarction: 
insights from the cardiac arrhythmia suppression trial (CAST). Clin Cardiol. 2000,23:187-94. 
[34] Allen, J. J., Chambers, A. S., Towers, D. N. The many metrics of cardiac chronotropy: a 
pragmatic primer and a brief comparison of metrics. Biol Psychol. 2007,74:243-62. 
[35] Akselrod, S., Gordon, D., Ubel, F. A., Shannon, D. C., Berger, A. C., Cohen, R. J. Power 
spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular 
control. Science. 1981,213:220-2. 
[36] Taylor, J. A., Carr, D. L., Myers, C. W., Eckberg, D. L. Mechanisms underlying very-low-
frequency RR-interval oscillations in humans. Circulation. 1998,98:547-55. 
[37] Carney, R. M., Freedland, K. E., Miller, G. E., Jaffe, A. S. Depression as a risk factor for 
cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 
2002,53:897-902. 
[38] Barefoot, J. C., Helms, M. J., Mark, D. B., Blumenthal, J. A., Califf, R. M., Haney, T. L., et 
al. Depression and long-term mortality risk in patients with coronary artery disease. Am J 
Cardiol. 1996,78:613-7. 
[39] Barefoot, J. C., Schroll, M. Symptoms of depression, acute myocardial infarction, and total 
mortality in a community sample. Circulation. 1996,93:1976-80. 
[40] Carney, R. M., Freedland, K. E. Depression, mortality, and medical morbidity in patients 
with coronary heart disease. Biol Psychiatry. 2003,54:241-7. 
[41] Frasure-Smith, N., Lesperance, F. Depression and cardiac risk: present status and future 
directions. Heart. 2010,96:173-6. 
[42] Frasure-Smith, N., Lesperance, F., Irwin, M. R., Talajic, M., Pollock, B. G. The 
relationships among heart rate variability, inflammatory markers and depression in coronary 
heart disease patients. Brain Behav Immun. 2009,23:1140-7. 
[43] Frasure-Smith, N., Lesperance, F., Habra, M., Talajic, M., Khairy, P., Dorian, P., et al. 
Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial 
fibrillation and heart failure. Circulation. 2009,120:134-40, 3p following 40. 
[44] Frasure-Smith, N., Lesperance, F. Depression--a cardiac risk factor in search of a treatment. 
JAMA. 2003,289:3171-3. 
[45] Frasure-Smith, N., Lesperance, F. Depression and other psychological risks following 
myocardial infarction. Arch Gen Psychiatry. 2003,60:627-36. 
[46] Willner, P. Chronic mild stress (CMS) revisited: consistency and behavioural-
neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005,52:90-110. 
[47] Willner, P. Validity, reliability and utility of the chronic mild stress model of depression: a 
10-year review and evaluation. Psychopharmacology (Berl). 1997,134:319-29. 
[48] Parihar, V. K., Hattiangady, B., Kuruba, R., Shuai, B., Shetty, A. K. Predictable chronic 
mild stress improves mood, hippocampal neurogenesis and memory. Mol Psychiatry. 
2011,16:171-83. 
 113 
[49] Grippo, A. J., Moffitt, J. A., Johnson, A. K. Cardiovascular alterations and autonomic 
imbalance in an experimental model of depression. Am J Physiol Regul Integr Comp Physiol. 
2002,282:R1333-41. 
[50] Grippo, A. J., Beltz, T. G., Johnson, A. K. Behavioral and cardiovascular changes in the 
chronic mild stress model of depression. Physiol Behav. 2003,78:703-10. 
[51] Grippo, A. J., Francis, J., Beltz, T. G., Felder, R. B., Johnson, A. K. Neuroendocrine and 
cytokine profile of chronic mild stress-induced anhedonia. Physiol Behav. 2005,84:697-706. 
[52] Grippo, A. J., Sullivan, N. R., Damjanoska, K. J., Crane, J. W., Carrasco, G. A., Shi, J., et 
al. Chronic mild stress induces behavioral and physiological changes, and may alter serotonin 1A 
receptor function, in male and cycling female rats. Psychopharmacology (Berl). 2005,179:769-
80. 
[53] Grippo, A. J., Beltz, T. G., Weiss, R. M., Johnson, A. K. The effects of chronic fluoxetine 
treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry. 
2006,59:309-16. 
[54] Gambarana, C., Tolu, P. L., Masi, F., Rinaldi, M., Giachetti, D., Morazzoni, P., et al. A 
study of the antidepressant activity of Hypericum perforatum on animal models. 
Pharmacopsychiatry. 2001,34 Suppl 1:S42-4. 
[55] Grippo, A. J., Francis, J., Weiss, R. M., Felder, R. B., Johnson, A. K. Cytokine mediation of 
experimental heart failure-induced anhedonia. Am J Physiol Regul Integr Comp Physiol. 
2003,284:R666-73. 
[56] Di Chiara, G., Tanda, G. Blunting of reactivity of dopamine transmission to palatable food: 
a biochemical marker of anhedonia in the CMS model? Psychopharmacology (Berl). 
1997,134:351-3; discussion 71-7. 
[57] Di Chiara, G., Loddo, P., Tanda, G. Reciprocal changes in prefrontal and limbic dopamine 
responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the 
psychobiology of depression. Biol Psychiatry. 1999,46:1624-33. 
[58] Jayatissa, M. N., Bisgaard, C., Tingstrom, A., Papp, M., Wiborg, O. Hippocampal 
cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of 
depression. Neuropsychopharmacology. 2006,31:2395-404. 
[59] Joeyen-Waldorf, J., Edgar, N., Sibille, E. The roles of sex and serotonin transporter levels in 
age- and stress-related emotionality in mice. Brain Res. 2009,1286:84-93. 
[60] Sampson, D., Willner, P., Muscat, R. Reversal of antidepressant action by dopamine 
antagonists in an animal model of depression. Psychopharmacology (Berl). 1991,104:491-5. 
[61] Muscat, R., Papp, M., Willner, P. Antidepressant-like effects of dopamine agonists in an 
animal model of depression. Biol Psychiatry. 1992,31:937-46. 
[62] Stein, E. J., da Silveira Filho, N. G., Machado, D. C., Hipolide, D. C., Barlow, K., Nobrega, 
J. N. Chronic mild stress induces widespread decreases in thyroid hormone alpha1 receptor 
mRNA levels in brain--reversal by imipramine. Psychoneuroendocrinology. 2009,34:281-6. 
[63] D'Aquila, P. S., Brain, P., Willner, P. Effects of chronic mild stress on performance in 
behavioural tests relevant to anxiety and depression. Physiol Behav. 1994,56:861-7. 
[64] Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., et al. Requirement 
of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 
2003,301:805-9. 
[65] Czeh, B., Muller-Keuker, J. I., Rygula, R., Abumaria, N., Hiemke, C., Domenici, E., et al. 
Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric 
asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology. 2007,32:1490-503. 
 114 
[66] Stout, S. C., Owens, M. J., Nemeroff, C. B. Regulation of corticotropin-releasing factor 
neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic 
antidepressant treatment. J Pharmacol Exp Ther. 2002,300:1085-92. 
[67] Grippo, A. J., Moffitt, J. A., Johnson, A. K. Evaluation of baroreceptor reflex function in the 
chronic mild stress rodent model of depression. Psychosom Med. 2008,70:435-43. 
[68] Grippo, A. J., Santos, C. M., Johnson, R. F., Beltz, T. G., Martins, J. B., Felder, R. B., et al.  
Increased susceptibility to ventricular arrhythmias in a rodent model of experimental depression. 
Am J Physiol Heart Circ Physiol. 2004,286:H619-26. 
[69] Fava, M., Kendler, K. S. Major depressive disorder. Neuron. 2000,28:335-41. 
[70] Feder, A., Nestler, E. J., Charney, D. S. Psychobiology and molecular genetics of resilience. 
Nat Rev Neurosci. 2009,10:446-57. 
[71] Stead, J. D., Clinton, S., Neal, C., Schneider, J., Jama, A., Miller, S., et al. Selective 
breeding for divergence in novelty-seeking traits: heritability and enrichment in spontaneous 
anxiety-related behaviors. Behav Genet. 2006,36:697-712. 
[72] Krishnan, V., Han, M. H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., et al. 
Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward 
regions. Cell. 2007,131:391-404. 
[73] Ballaz, S. J., Akil, H., Watson, S. J. Previous experience affects subsequent anxiety-like 
responses in rats bred for novelty seeking. Behav Neurosci. 2007,121:1113-8. 
[74] Tonissaar, M., Herm, L., Eller, M., Koiv, K., Rinken, A., Harro, J. Rats with high or low 
sociability are differently affected by chronic variable stress. Neuroscience. 2008,152:867-76. 
[75] Touma, C., Bunck, M., Glasl, L., Nussbaumer, M., Palme, R., Stein, H., et al. Mice selected 
for high versus low stress reactivity: a new animal model for affective disorders. 
Psychoneuroendocrinology. 2008,33:839-62. 
[76] Kabbaj, M., Devine, D. P., Savage, V. R., Akil, H. Neurobiological correlates of individual 
differences in novelty-seeking behavior in the rat: differential expression of stress-related 
molecules. J Neurosci. 2000,20:6983-8. 
[77] Mallo, T., Alttoa, A., Koiv, K., Tonissaar, M., Eller, M., Harro, J. Rats with persistently low 
or high exploratory activity: behaviour in tests of anxiety and depression, and extracellular levels 
of dopamine. Behav Brain Res. 2007,177:269-81. 
[78] Pawlak, C. R., Ho, Y. J., Schwarting, R. K. Animal models of human psychopathology 
based on individual differences in novelty-seeking and anxiety. Neurosci Biobehav Rev. 
2008,32:1544-68. 
[79] Dellu, F., Piazza, P. V., Mayo, W., Le Moal, M., Simon, H. Novelty-seeking in rats--
biobehavioral characteristics and possible relationship with the sensation-seeking trait in man. 
Neuropsychobiology. 1996,34:136-45. 
[80] Jama, A., Cecchi, M., Calvo, N., Watson, S. J., Akil, H. Inter-individual differences in 
novelty-seeking behavior in rats predict differential responses to desipramine in the forced swim 
test. Psychopharmacology (Berl). 2008,198:333-40. 
[81] Clinton, S. M., Vazquez, D. M., Kabbaj, M., Kabbaj, M. H., Watson, S. J., Akil, H. 
Individual differences in novelty-seeking and emotional reactivity correlate with variation in 
maternal behavior. Horm Behav. 2007,51:655-64. 
[82] Glassman, A. H., Bigger, J. T., Jr. Cardiovascular effects of therapeutic doses of tricyclic 
antidepressants. A review. Arch Gen Psychiatry. 1981,38:815-20. 
[83] Glassman, A. H., Rodriguez, A. I., Shapiro, P. A. The use of antidepressant drugs in patients 
with heart disease. J Clin Psychiatry. 1998,59 Suppl 10:16-21. 
 115 
[84] Sheline, Y. I., Freedland, K. E., Carney, R. M. How safe are serotonin reuptake inhibitors 
for depression in patients with coronary heart disease? Am J Med. 1997,102:54-9. 
[85] Warrington, S. J., Padgham, C., Lader, M. The cardiovascular effects of antidepressants. 
Psychol Med Monogr Suppl. 1989,16:i-iii, 1-40. 
[86] Stern, T. A. The management of depression and anxiety following myocardial infarction. Mt 
Sinai J Med. 1985,52:623-33. 
[87] Glassman, A. H. Does treating post-myocardial infarction depression reduce medical 
mortality? Arch Gen Psychiatry. 2005,62:711-2. 
[88] Jiang, W., Krishnan, R., Kuchibhatla, M., Cuffe, M. S., Martsberger, C., Arias, R. M., et al. 
Characteristics of depression remission and its relation with cardiovascular outcome among 
patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol. 
2011,107:545-51. 
[89] Fosbol, E. L., Gislason, G. H., Poulsen, H. E., Hansen, M. L., Folke, F., Schramm, T. K., et 
al. Prognosis in heart failure and the value of {beta}-blockers are altered by the use of 
antidepressants and depend on the type of antidepressants used. Circ Heart Fail. 2009,2:582-90. 
[90] Berkman, L. F., Blumenthal, J., Burg, M., Carney, R. M., Catellier, D., Cowan, M. J., et al.  
Effects of treating depression and low perceived social support on clinical events after 
myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) 
Randomized Trial. JAMA. 2003,289:3106-16. 
[91] Jezova, D., Ochedalski, T., Kiss, A., Aguilera, G. Brain angiotensin II modulates 
sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J 
Neuroendocrinol. 1998,10:67-72. 
[92] Saavedra, J. M. Brain angiotensin II: new developments, unanswered questions and 
therapeutic opportunities. Cell Mol Neurobiol. 2005,25:485-512. 
[93] Packer, M. The neurohormonal hypothesis: a theory to explain the mechanism of disease 
progression in heart failure. J Am Coll Cardiol. 1992,20:248-54. 
[94] Fyhrquist, F., Metsarinne, K., Tikkanen, I. Role of angiotensin II in blood pressure 
regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995,9 
Suppl 5:S19-24. 
[95] Ostergren, J. B. Angiotensin receptor blockade with candesartan in heart failure: findings 
from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity 
(CHARM) programme. J Hypertens Suppl. 2006,24:S3-7. 
[96] Nap, A., Balt, J. C., Mathy, M. J., Van Zwieten, P. A. AT(1)-receptor blockade and 
sympathetic neurotransmission in cardiovascular disease. Auton Autacoid Pharmacol. 
2003,23:285-96. 
[97] Saavedra, J. M. Brain and pituitary angiotensin. Endocr Rev. 1992,13:329-80. 
[98] Tsutsumi, K., Saavedra, J. M. Characterization and development of angiotensin II receptor 
subtypes (AT1 and AT2) in rat brain. Am J Physiol. 1991,261:R209-16. 
[99] Aguilera, G., Young, W. S., Kiss, A., Bathia, A. Direct regulation of hypothalamic 
corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology. 1995,61:437-
44. 
[100] Armando, I., Volpi, S., Aguilera, G., Saavedra, J. M. Angiotensin II AT1 receptor 
blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. 
Brain Res. 2007,1142:92-9. 
[101] Saavedra, J. M., Armando, I., Bregonzio, C., Juorio, A., Macova, M., Pavel, J., et al. A 
centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-
 116 
induced decrease in cortical CRF1 receptor and benzodiazepine binding. 
Neuropsychopharmacology. 2006,31:1123-34. 
[102] Bregonzio, C., Armando, I., Ando, H., Jezova, M., Baiardi, G., Saavedra, J. M. Anti-
inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric 
injury. Am J Physiol Gastrointest Liver Physiol. 2003,285:G414-23. 
[103] Bregonzio, C., Armando, I., Ando, H., Jezova, M., Baiardi, G., Saavedra, J. M. 
Angiotensin II AT1 receptor blockade prevents gastric ulcers during cold-restraint stress. Ann N 
Y Acad Sci. 2004,1018:351-5. 
[104] Germain, L., Chouinard, G. Treatment of recurrent unipolar major depression with 
captopril. Biol Psychiatry. 1988,23:637-41. 
[105] Domeney, A. M. Angiotensin converting enzyme inhibitors as potential cognitive 
enhancing agents. J Psychiatry Neurosci. 1994,19:46-50. 
[106] Nasr, S. J., Crayton, J. W., Agarwal, B., Wendt, B., Kora, R. Lower frequency of 
antidepressant use in patients on Renin-Angiotensin-aldosterone system modifying medications. 
Cell Mol Neurobiol. 2011,31:615-8. 
[107] Giardina, W. J., Ebert, D. M. Positive effects of captopril in the behavioral despair swim 
test. Biol Psychiatry. 1989,25:697-702. 
[108] Gard, P. R., Mandy, A., Sutcliffe, M. A. Evidence of a possible role of altered angiotensin 
function in the treatment, but not etiology, of depression. Biol Psychiatry. 1999,45:1030-4. 
[109] Kessler, R. C. The effects of stressful life events on depression. Annu Rev Psychol. 
1997,48:191-214. 
[110] Willner, P., Mitchell, P. J. The validity of animal models of predisposition to depression. 
Behav Pharmacol. 2002,13:169-88. 
[111] Gronli, J., Murison, R., Bjorvatn, B., Sorensen, E., Portas, C. M., Ursin, R. Chronic mild 
stress affects sucrose intake and sleep in rats. Behav Brain Res. 2004,150:139-47. 
[112] Mitchell, P. J. Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol. 
2005,526:147-62. 
[113] Johnson, A. K., Grippo, A. J. Sadness and broken hearts: neurohumoral mechanisms and 
co-morbidity of ischemic heart disease and psychological depression. J Physiol Pharmacol. 
2006,57 Suppl 11:5-29. 
[114] Bondi, C. O., Rodriguez, G., Gould, G. G., Frazer, A., Morilak, D. A. Chronic 
unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented 
by chronic antidepressant drug treatment. Neuropsychopharmacology. 2008,33:320-31. 
[115] Dulawa, S. C., Hen, R. Recent advances in animal models of chronic antidepressant 
effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev. 2005,29:771-83. 
[116] Bodnoff, S. R., Suranyi-Cadotte, B., Aitken, D. H., Quirion, R., Meaney, M. J. The effects 
of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl). 
1988,95:298-302. 
[117] Bessa, J. M., Mesquita, A. R., Oliveira, M., Pego, J. M., Cerqueira, J. J., Palha, J. A., et al. 
A trans-dimensional approach to the behavioral aspects of depression. Front Behav Neurosci. 
2009,3:1. 
[118] Martinez, V., Rivier, J., Wang, L., Tache, Y. Central injection of a new corticotropin-
releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric 
and colonic motor function. J Pharmacol Exp Ther. 1997,280:754-60. 
[119] Bonaz, B., Tache, Y. Water-avoidance stress-induced c-fos expression in the rat brain and 
stimulation of fecal output: role of corticotropin-releasing factor. Brain Res. 1994,641:21-8. 
 117 
[120] Stam, R., Croiset, G., Akkermans, L. M., Wiegant, V. M. Psychoneurogastroenterology: 
interrelations in stress-induced colonic motility and behavior. Physiol Behav. 1999,65:679-84. 
[121] Cecchi, M., Khoshbouei, H., Javors, M., Morilak, D. A. Modulatory effects of 
norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine 
responses to acute stress. Neuroscience. 2002,112:13-21. 
[122] Hooks, M. S., Jones, G. H., Smith, A. D., Neill, D. B., Justice, J. B., Jr. Response to 
novelty predicts the locomotor and nucleus accumbens dopamine response to cocaine. Synapse. 
1991,9:121-8. 
[123] Davis, B. A., Clinton, S. M., Akil, H., Becker, J. B. The effects of novelty-seeking 
phenotypes and sex differences on acquisition of cocaine self-administration in selectively bred 
High-Responder and Low-Responder rats. Pharmacol Biochem Behav. 2008,90:331-8. 
[124] Flagel, S. B., Robinson, T. E., Clark, J. J., Clinton, S. M., Watson, S. J., Seeman, P., et al. 
An animal model of genetic vulnerability to behavioral disinhibition and responsiveness to 
reward-related cues: implications for addiction. Neuropsychopharmacology. 2010,35:388-400. 
[125] Rush, A. J., Weissenburger, J. E. Melancholic symptom features and DSM-IV. Am J 
Psychiatry. 1994,151:489-98. 
[126] Melartin, T., Leskela, U., Rytsala, H., Sokero, P., Lestela-Mielonen, P., Isometsa, E. Co-
morbidity and stability of melancholic features in DSM-IV major depressive disorder. Psychol 
Med. 2004,34:1443-52. 
[127] Loas, G. Vulnerability to depression: a model centered on anhedonia. J Affect Disord. 
1996,41:39-53. 
[128] Mitchell, P. B., Parker, G. B., Gladstone, G. L., Wilhelm, K., Austin, M. P. Severity of 
stressful life events in first and subsequent episodes of depression: the relevance of depressive 
subtype. J Affect Disord. 2003,73:245-52. 
[129] Harkness, K. L., Monroe, S. M. Severe melancholic depression is more vulnerable than 
non-melancholic depression to minor precipitating life events. J Affect Disord. 2006,91:257-63. 
[130] Bogdan, R., Pizzagalli, D. A. Acute stress reduces reward responsiveness: implications for 
depression. Biol Psychiatry. 2006,60:1147-54. 
[131] Horesh, N., Klomek, A. B., Apter, A. Stressful life events and major depressive disorders. 
Psychiatry Res. 2008,160:192-9. 
[132] Muscatell, K. A., Slavich, G. M., Monroe, S. M., Gotlib, I. H. Stressful life events, chronic 
difficulties, and the symptoms of clinical depression. J Nerv Ment Dis. 2009,197:154-60. 
[133] Gorwood, P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci. 
2008,10:291-9. 
[134] Martin-Soelch, C. Is depression associated with dysfunction of the central reward system? 
Biochem Soc Trans. 2009,37:313-7. 
[135] Gold, P. W., Gabry, K. E., Yasuda, M. R., Chrousos, G. P. Divergent endocrine 
abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. 
Endocrinol Metab Clin North Am. 2002,31:37-62, vi. 
[136] Gold, P. W., Chrousos, G. P. Organization of the stress system and its dysregulation in 
melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry. 2002,7:254-
75. 
[137] Meynen, G., Unmehopa, U. A., van Heerikhuize, J. J., Hofman, M. A., Swaab, D. F., 
Hoogendijk, W. J. Increased arginine vasopressin mRNA expression in the human hypothalamus 
in depression: A preliminary report. Biol Psychiatry. 2006,60:892-5. 
 118 
[138] Kessler, R. C., Gruber, M., Hettema, J. M., Hwang, I., Sampson, N., Yonkers, K. A. Co-
morbid major depression and generalized anxiety disorders in the National Comorbidity Survey 
follow-up. Psychol Med. 2008,38:365-74. 
[139] Beesdo, K., Pine, D. S., Lieb, R., Wittchen, H. U. Incidence and risk patterns of anxiety 
and depressive disorders and categorization of generalized anxiety disorder. Arch Gen 
Psychiatry. 2010,67:47-57. 
[140] Morilak, D. A., Frazer, A. Antidepressants and brain monoaminergic systems: a 
dimensional approach to understanding their behavioural effects in depression and anxiety 
disorders. Int J Neuropsychopharmacol. 2004,7:193-218. 
[141] Mineka, S., Watson, D., Clark, L. A. Comorbidity of anxiety and unipolar mood disorders. 
Annu Rev Psychol. 1998,49:377-412. 
[142] Regier, D. A., Rae, D. S., Narrow, W. E., Kaelber, C. T., Schatzberg, A. F. Prevalence of 
anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry 
Suppl. 1998:24-8. 
[143] Flint, A. J., Rifat, S. L. Two-year outcome of elderly patients with anxious depression. 
Psychiatry Res. 1997,66:23-31. 
[144] Overstreet, D. H., Friedman, E., Mathe, A. A., Yadid, G. The Flinders Sensitive Line rat: a 
selectively bred putative animal model of depression. Neurosci Biobehav Rev. 2005,29:739-59. 
[145] Overstreet, D. H., Pucilowski, O., Djuric, V. Genetic/environment interactions in chronic 
mild stress. Psychopharmacology (Berl). 1997,134:359-60; discussion 71-7. 
[146] Matthews, K., Baldo, B. A., Markou, A., Lown, O., Overstreet, D. H., Koob, G. F. 
Rewarding electrical brain stimulation: similar thresholds for Flinders Sensitive Line 
Hypercholinergic and Flinders Resistant Line Hypocholinergic rats. Physiol Behav. 
1996,59:1155-62. 
[147] Ayensu, W. K., Pucilowski, O., Mason, G. A., Overstreet, D. H., Rezvani, A. H., 
Janowsky, D. S. Effects of chronic mild stress on serum complement activity, saccharin 
preference, and corticosterone levels in Flinders lines of rats. Physiol Behav. 1995,57:165-9. 
[148] Landgraf, R., Wigger, A. High vs low anxiety-related behavior rats: an animal model of 
extremes in trait anxiety. Behav Genet. 2002,32:301-14. 
[149] Ohl, F., Toschi, N., Wigger, A., Henniger, M. S., Landgraf, R. Dimensions of emotionality 
in a rat model of innate anxiety. Behav Neurosci. 2001,115:429-36. 
[150] Bosch, O. J., Kromer, S. A., Neumann, I. D. Prenatal stress: opposite effects on anxiety 
and hypothalamic expression of vasopressin and corticotropin-releasing hormone in rats 
selectively bred for high and low anxiety. Eur J Neurosci. 2006,23:541-51. 
[151] Cryan, J. F., Valentino, R. J., Lucki, I. Assessing substrates underlying the behavioral 
effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 
2005,29:547-69. 
[152] Neumann, I. D., Wegener, G., Homberg, J. R., Cohen, H., Slattery, D. A., Zohar, J., et al. 
Animal models of depression and anxiety: What do they tell us about human condition? Prog 
Neuropsychopharmacol Biol Psychiatry. 2010. 
[153] Veenema, A. H., Torner, L., Blume, A., Beiderbeck, D. I., Neumann, I. D. Low inborn 
anxiety correlates with high intermale aggression: link to ACTH response and neuronal 
activation of the hypothalamic paraventricular nucleus. Horm Behav. 2007,51:11-9. 
[154] Homberg, J. R., Olivier, J. D., Smits, B. M., Mul, J. D., Mudde, J., Verheul, M., et al. 
Characterization of the serotonin transporter knockout rat: a selective change in the functioning 
of the serotonergic system. Neuroscience. 2007,146:1662-76. 
 119 
[155] Olivier, J. D., Van Der Hart, M. G., Van Swelm, R. P., Dederen, P. J., Homberg, J. R., 
Cremers, T., et al. A study in male and female 5-HT transporter knockout rats: an animal model 
for anxiety and depression disorders. Neuroscience. 2008,152:573-84. 
[156] Holmes, A., Yang, R. J., Murphy, D. L., Crawley, J. N. Evaluation of antidepressant-
related behavioral responses in mice lacking the serotonin transporter. 
Neuropsychopharmacology. 2002,27:914-23. 
[157] Lira, A., Zhou, M., Castanon, N., Ansorge, M. S., Gordon, J. A., Francis, J. H., et al. 
Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of 
serotonin transporter-deficient mice. Biol Psychiatry. 2003,54:960-71. 
[158] Grippo, A. J. Mechanisms underlying altered mood and cardiovascular dysfunction: the 
value of neurobiological and behavioral research with animal models. Neurosci Biobehav Rev. 
2009,33:171-80. 
[159] Berntson, G. G., Bigger, J. T., Jr., Eckberg, D. L., Grossman, P., Kaufmann, P. G., Malik, 
M., et al. Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology. 
1997,34:623-48. 
[160] Stedenfeld, K. A., Clinton, S. M., Kerman, I. A., Akil, H., Watson, S. J., Sved, A. F. 
Novelty-seeking behavior predicts vulnerability in a rodent model of depression. Physiol Behav. 
2011,103:210-6. 
[161] Clinton, S., Miller, S., Watson, S. J., Akil, H. Prenatal stress does not alter innate novelty-
seeking behavioral traits, but differentially affects individual differences in neuroendocrine stress 
responsivity. Psychoneuroendocrinology. 2008,33:162-77. 
[162] Hildreth, C. M., Padley, J. R., Pilowsky, P. M., Goodchild, A. K. Impaired serotonergic 
regulation of heart rate may underlie reduced baroreflex sensitivity in an animal model of 
depression. Am J Physiol Heart Circ Physiol. 2008,294:H474-80. 
[163] Henze, M., Hart, D., Samarel, A., Barakat, J., Eckert, L., Scrogin, K. Persistent alterations 
in heart rate variability, baroreflex sensitivity, and anxiety-like behaviors during development of 
heart failure in the rat. Am J Physiol Heart Circ Physiol. 2008,295:H29-38. 
[164] Carney, R. M., Steinmeyer, B., Freedland, K. E., Blumenthal, J. A., Stein, P. K., Steinhoff, 
W. A., et al. Nighttime heart rate and survival in depressed patients post acute myocardial 
infarction. Psychosom Med. 2008,70:757-63. 
[165] Pitzalis, M. V., Iacoviello, M., Todarello, O., Fioretti, A., Guida, P., Massari, F., et al. 
Depression but not anxiety influences the autonomic control of heart rate after myocardial 
infarction. Am Heart J. 2001,141:765-71. 
[166] Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., et al. 
Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007,50:823-30. 
[167] Grippo, A. J., Lamb, D. G., Carter, C. S., Porges, S. W. Social isolation disrupts autonomic 
regulation of the heart and influences negative affective behaviors. Biol Psychiatry. 
2007,62:1162-70. 
[168] Japundzic, N., Grichois, M. L., Zitoun, P., Laude, D., Elghozi, J. L. Spectral analysis of 
blood pressure and heart rate in conscious rats: effects of autonomic blockers. J Auton Nerv Syst. 
1990,30:91-100. 
[169] Padley, J. R., Overstreet, D. H., Pilowsky, P. M., Goodchild, A. K. Impaired cardiac and 
sympathetic autonomic control in rats differing in acetylcholine receptor sensitivity. Am J 
Physiol Heart Circ Physiol. 2005,289:H1985-92. 
 120 
[170] Anda, R., Williamson, D., Jones, D., Macera, C., Eaker, E., Glassman, A., et al. Depressed 
affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. 
Epidemiology. 1993,4:285-94. 
[171] Pavel, J., Benicky, J., Murakami, Y., Sanchez-Lemus, E., Saavedra, J. M. Peripherally 
administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann N 
Y Acad Sci. 2008,1148:360-6. 
[172] Porsolt, R. D., Anton, G., Blavet, N., Jalfre, M. Behavioural despair in rats: a new model 
sensitive to antidepressant treatments. Eur J Pharmacol. 1978,47:379-91. 
[173] Detke, M. J., Rickels, M., Lucki, I. Active behaviors in the rat forced swimming test 
differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 
(Berl). 1995,121:66-72. 
[174] Saavedra, J. M., Ando, H., Armando, I., Baiardi, G., Bregonzio, C., Juorio, A., et al. Anti-
stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul 
Pept. 2005,128:227-38. 
[175] Charney, D. S., Grothe, D. R., Smith, S. L., Brady, K. T., Kaltsounis-Puckett, J., Wright, 
C. W., et al. Overview of psychiatric disorders and the role of newer antidepressants. J Clin 
Psychiatry. 2002,63 Suppl 1:3-9. 
[176] Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., et 
al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force 
report based on a review of evidence. Int J Neuropsychopharmacol. 2007,10 Suppl 1:S1-207. 
[177] Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., 
et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication 
treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006,163:1161-72. 
[178] Ni, W., Watts, S. W. 5-hydroxytryptamine in the cardiovascular system: focus on the 
serotonin transporter (SERT). Clin Exp Pharmacol Physiol. 2006,33:575-83. 
[179] Moja, P. L., Cusi, C., Sterzi, R. R., Canepari, C. Selective serotonin re-uptake inhibitors 
(SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 
2005:CD002919. 
[180] Baldo, P., Doree, C., Lazzarini, R., Molin, P., McFerran, D. J. Antidepressants for patients 
with tinnitus. Cochrane Database Syst Rev. 2006:CD003853. 
[181] Wang, W. F., Chang, L., Minhas, S., Ralph, D. J. Selective serotonin reuptake inhibitors in 
the treatment of premature ejaculation. Chin Med J (Engl). 2007,120:1000-6. 
[182] Borsini, F., Meli, A. Is the forced swimming test a suitable model for revealing 
antidepressant activity? Psychopharmacology (Berl). 1988,94:147-60. 
[183] Duman, C. H. Models of depression. Vitam Horm. 2010,82:1-21. 
[184] Van de Kar, L. D., Rittenhouse, P. A., Li, Q., Levy, A. D. Serotonergic regulation of renin 
and prolactin secretion. Behav Brain Res. 1996,73:203-8. 
[185] Stedenfeld, K. A., Parrish, J.N. and Sved, A.F. Candesartan, an angiotensin type 1 receptor 
antagonist, shows positive effects in screening tests of antidepressant drug action The FASEB 
Journal2011. p. 848.12. 
[186] Nalivaiko, E. 5-HT(1A) receptors in stress-induced cardiac changes: a possible link 
between mental and cardiac disorders. Clin Exp Pharmacol Physiol. 2006,33:1259-64. 
[187] Malberg, J. E., Eisch, A. J., Nestler, E. J., Duman, R. S. Chronic antidepressant treatment 
increases neurogenesis in adult rat hippocampus. J Neurosci. 2000,20:9104-10. 
[188] Duman, R. S. Depression: a case of neuronal life and death? Biol Psychiatry. 2004,56:140-
5. 
 121 
[189] Armando, I., Carranza, A., Nishimura, Y., Hoe, K. L., Barontini, M., Terron, J. A., et al. 
Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the 
hypothalamic-pituitary-adrenal response to isolation Stress. Endocrinology. 2001,142:3880-9. 
[190] Nishimura, Y., Ito, T., Hoe, K., Saavedra, J. M. Chronic peripheral administration of the 
angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res. 
2000,871:29-38. 
[191] Saavedra, J. M., Sanchez-Lemus, E., Benicky, J. Blockade of brain angiotensin II AT1 
receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. 
Psychoneuroendocrinology. 2011,36:1-18. 
[192] Benicky, J., Sanchez-Lemus, E., Pavel, J., Saavedra, J. M. Anti-inflammatory effects of 
angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol. 2009,29:781-
92. 
[193] Sanchez-Lemus, E., Benicky, J., Pavel, J., Larrayoz, I. M., Zhou, J., Baliova, M., et al. 
Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in 
rat spleen. Am J Physiol Regul Integr Comp Physiol. 2009,296:R1376-84. 
[194] Ridker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., Braunwald, E. Elevation of 
tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial 
infarction. Circulation. 2000,101:2149-53. 
[195] Ridker, P. M., Rifai, N., Stampfer, M. J., Hennekens, C. H. Plasma concentration of 
interleukin-6 and the risk of future myocardial infarction among apparently healthy men. 
Circulation. 2000,101:1767-72. 
[196] Levine, B., Kalman, J., Mayer, L., Fillit, H. M., Packer, M. Elevated circulating levels of 
tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990,323:236-41. 
[197] Eklind-Cervenka, M., Benson, L., Dahlstrom, U., Edner, M., Rosenqvist, M., Lund, L. H. 
Association of candesartan vs losartan with all-cause mortality in patients with heart failure. 
JAMA. 2011,305:175-82. 
[198] Grippo, A. J., Moffitt, J. A., Beltz, T. G., Johnson, A. K. Reduced hedonic behavior and 
altered cardiovascular function induced by mild sodium depletion in rats. Behav Neurosci. 
2006,120:1133-43. 
[199] Rinaman, L., Banihashemi, L., Koehnle, T. J. Early life experience shapes the functional 
organization of stress-responsive visceral circuits. Physiol Behav. 2011. 
[200] Grippo, A. J., Johnson, A. K. Biological mechanisms in the relationship between 
depression and heart disease. Neurosci Biobehav Rev. 2002,26:941-62. 
[201] de Kloet, E. R., Joels, M., Holsboer, F. Stress and the brain: from adaptation to disease. 
Nat Rev Neurosci. 2005,6:463-75. 
[202] Banki, C. M., Karmacsi, L., Bissette, G., Nemeroff, C. B. CSF corticotropin-releasing 
hormone and somatostatin in major depression: response to antidepressant treatment and relapse. 
Eur Neuropsychopharmacol. 1992,2:107-13. 
[203] Brown, M. R., Fisher, L. A., Spiess, J., Rivier, C., Rivier, J., Vale, W. Corticotropin-
releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology. 
1982,111:928-31. 
[204] Israel, A., Stromberg, C., Tsutsumi, K., Garrido, M. R., Torres, M., Saavedra, J. M. 
Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Brain 
Res Bull. 1995,38:441-6. 
 122 
[205] Bourassa, E. A., Sved, A. F., Speth, R. C. Anteroposterior distribution of AT(1) 
angiotensin receptors in caudal brainstem cardiovascular regulatory centers of the rat. Brain Res. 
2010,1306:69-76. 
[206] Bourassa, E. A., Sved, A. F., Speth, R. C. Angiotensin modulation of rostral ventrolateral 
medulla (RVLM) in cardiovascular regulation. Mol Cell Endocrinol. 2009,302:167-75. 
[207] Esposito, M. S., Piatti, V. C., Laplagne, D. A., Morgenstern, N. A., Ferrari, C. C., Pitossi, 
F. J., et al. Neuronal differentiation in the adult hippocampus recapitulates embryonic 
development. J Neurosci. 2005,25:10074-86. 
[208] Ngwenya, L. B., Peters, A., Rosene, D. L. Maturational sequence of newly generated 
neurons in the dentate gyrus of the young adult rhesus monkey. J Comp Neurol. 2006,498:204-
16. 
[209] Schroder, D., Heger, J., Piper, H. M., Euler, G. Angiotensin II stimulates apoptosis via 
TGF-beta1 signaling in ventricular cardiomyocytes of rat. J Mol Med. 2006,84:975-83. 
[210] Conner, K. R., Payne, V. S., Forbes, M. E., Robbins, M. E., Riddle, D. R. Effects of the 
AT1 receptor antagonist L-158,809 on microglia and neurogenesis after fractionated whole-brain 
irradiation. Radiat Res. 2010,173:49-61. 
[211] Conner, K. R., Forbes, M. E., Lee, W. H., Lee, Y. W., Riddle, D. AT1 Receptor 
Antagonism Does Not Influence Early Radiation-Induced Changes in Microglial Activation or 
Neurogenesis in the Normal Rat Brain. Radiat Res. 2011. 
[212] Mukuda, T., Sugiyama, H. An angiotensin II receptor antagonist suppresses running-
enhanced hippocampal neurogenesis in rat. Neurosci Res. 2007,58:140-4. 
[213] Das, U. N. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial 
infarction. Mol Cell Biochem. 2000,215:145-52. 
[214] Ando, H., Zhou, J., Macova, M., Imboden, H., Saavedra, J. M. Angiotensin II AT1 
receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of 
spontaneously hypertensive rats. Stroke. 2004,35:1726-31. 
[215] Dalmay, F., Mazouz, H., Allard, J., Pesteil, F., Achard, J. M., Fournier, A. Non-AT(1)-
receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J 
Renin Angiotensin Aldosterone Syst. 2001,2:103-6. 
[216] Engelhorn, T., Goerike, S., Doerfler, A., Okorn, C., Forsting, M., Heusch, G., et al. The 
angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct 
size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood 
Flow Metab. 2004,24:467-74. 
[217] Hamai, M., Iwai, M., Ide, A., Tomochika, H., Tomono, Y., Mogi, M., et al. Comparison of 
inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative 
stress. Neuropharmacology. 2006,51:822-8. 
[218] Liu, H., Kitazato, K. T., Uno, M., Yagi, K., Kanematsu, Y., Tamura, T., et al. Protective 
mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: 
in-vivo and in-vitro studies. J Hypertens. 2008,26:1435-45. 
[219] Ishizaki, J., Yamamoto, H., Takahashi, T., Takeda, M., Yano, M., Mimura, M. Changes in 
regional cerebral blood flow following antidepressant treatment in late-life depression. Int J 
Geriatr Psychiatry. 2008,23:805-11. 
[220] Kohn, Y., Freedman, N., Lester, H., Krausz, Y., Chisin, R., Lerer, B., et al. 99mTc-
HMPAO SPECT study of cerebral perfusion after treatment with medication and 
electroconvulsive therapy in major depression. J Nucl Med. 2007,48:1273-8. 
 123 
[221] Chen, Y., Wan, H. I., O'Reardon, J. P., Wang, D. J., Wang, Z., Korczykowski, M., et al. 
Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI 
after a single dose of oral citalopram. Clin Pharmacol Ther. 2011,89:251-8. 
[222] Duclot, F., Hollis, F., Darcy, M. J., Kabbaj, M. Individual differences in novelty-seeking 
behavior in rats as a model for psychosocial stress-related mood disorders. Physiol Behav. 2010. 
[223] Taylor, C. B., Youngblood, M. E., Catellier, D., Veith, R. C., Carney, R. M., Burg, M. M., 
et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after 
myocardial infarction. Arch Gen Psychiatry. 2005,62:792-8. 
[224] Moncrieff, J., Kirsch, I. Efficacy of antidepressants in adults. BMJ. 2005,331:155-7. 
[225] Grippo, A. J., Trahanas, D. M., Zimmerman, R. R., 2nd, Porges, S. W., Carter, C. S. 
Oxytocin protects against negative behavioral and autonomic consequences of long-term social 
isolation. Psychoneuroendocrinology. 2009,34:1542-53. 
[226] Griebel, G., Simiand, J., Stemmelin, J., Gal, C. S., Steinberg, R. The vasopressin V1b 
receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol 
Disord. 2003,2:191-200. 
[227] Eser, D., Baghai, T. C., Moller, H. J. Agomelatine: The evidence for its place in the 
treatment of depression. Core Evid. 2010,4:171-9. 
[228] Gurwitz, D., Weizman, A. New drug targets for depression and anxiety: Is the peptides era 
arriving? Drug Development Research. 2005,65:93-6. 
[229] Pinto-Foltz, M. D., Logsdon, M. C. Stigma towards mental illness: a concept analysis 
using postpartum depression as an exemplar. Issues Ment Health Nurs. 2008,29:21-36. 
[230] Goodman, J. H. Women's attitudes, preferences, and perceived barriers to treatment for 
perinatal depression. Birth. 2009,36:60-9. 
[231] Greden, J. F., Valenstein, M., Spinner, J., Blow, A., Gorman, L. A., Dalack, G. W., et al. 
Buddy-to-Buddy, a citizen soldier peer support program to counteract stigma, PTSD, depression, 
and suicide. Ann N Y Acad Sci. 2010,1208:90-7. 
[232] Olden, M., Cukor, J., Rizzo, A. S., Rothbaum, B., Difede, J. House calls revisited: 
leveraging technology to overcome obstacles to veteran psychiatric care and improve treatment 
outcomes. Ann N Y Acad Sci. 2010,1208:133-41. 
 
 
